The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
Studies have indicated that restriction of caloric intake by food deprivation slows down certain undesirable cellular processes in laboratory animals, many associated with aging and age-related diseases.
C-reactive protein (abbreviated as CRP) is one kind of acute phase protein, and although its blood level rapidly increases on inflammatory diseases or the like accompanying the disorganization, it is present in healthy mammal blood.
The inflammatory response plays an important role in the onset, development and evolution of stress, cardiac ischemia, and arthritic changes. Elevated serum levels of C-reactive protein (CRP) are non-specific but sensitive markers of the acute inflammatory response. C-reactive protein is an acute phase reactant protein. However, C-reactive protein levels can increase up to 100 or even 500 times during acute inflammation. This staggering response is mainly regulated by proinflammatory cytokines, in particular interleukin-6, and is largely unaffected by anti-inflammatory drugs and hormones. This suggests that the proinflammatory effects of C-reactive protein may contribute to the adverse outcome associated with higher levels of this acute phase reactant protein.
Additionally, due to its ligand binding properties, C-reactive protein plays a part in the innate immunity (opsonization) and in the removal of membrane and nuclear material from necrotic cells. C-reactive protein can also bind to complement factor Clq and factor H and activate the classic pathway of complement activation. C-reactive protein is present in atherosclerotic plaques but not in the normal vessel wall where often co-localize with the terminal complement complex. C-reactive protein can also induce tissue factor expression by monocytes.
There still exists a need for a method for decreasing inflammation and stress in a mammal resulting in enhancement of quality of life of a mammal, increase the length of the lifespan of a mammal, and providing for a healthier mammal.
It is therefore an object of the present invention to provide a method for decreasing inflammation and stress in a mammal including a human and/or a companion animal comprising; administration to a mammal a composition comprising a glucose anti-metabolite, avocado, avocado extract or mannoheptulose; and wherein the composition comprises amounts of the glucose anti-metabolite, avocado extract, avocado or mannoheptulose sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite, avocado extract, avocado or mannoheptulose.
The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein the composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
The present invention further relates to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising an avocado; and wherein the composition comprises amounts of the avocado sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado.
The present invention further relates to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising an avocado extract; and wherein the composition comprises amounts of the avocado extract sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado extract.
The present invention further relates to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising mannoheptulose; and wherein the composition comprises amounts of the mannoheptulose sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the mannoheptulose.
The method for the present invention comprises decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein the composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
These and other limitations of the compositions and methods of the present invention, as well as many of the optional ingredients suitable for use herein, are described in detail hereinafter.
As used herein, the term “adapted for use” means that the composition described can meet the American Association of Feed Control Officials (AAFCO) safety requirements for providing animal food products for an animal as may be amended from time to time.
As used herein, the term “companion animal” means an animal preferably including (for example) dogs, cats, kitten, puppy, senior dog, senior cat, adult dog, adult cat, horses, cows, pigs, rabbits, guinea pig, hamster, gerbil, ferret, horses, zoo mammals, fish, birds and the like. Dogs, cats, kitten, puppy, senior dog, senior cat, adult dog, adult cat are particularly preferred.
As used herein, the term “composition” means a composition that can be administered to a human that is orally ingested by the human, bars, pills, capsules, administered to companion animal that is orally ingested by a companion animal, supplements for a companion animal, pet food, dog food, cat food, treats, biscuits, raw hide, treats, chews, fillers, gravy, sauce, beverage, supplemental water, and combinations thereof. The composition can be wet, moist, and/or dry.
The term “complete and nutritionally balanced” as used herein, unless otherwise specified, refers to a composition having all known required nutrients in proper amounts and proportions based upon the recommendation of recognized authorities in the field of animal nutrition.
As used herein, the term “mammal” includes humans and/or companion animals.
All percentages, parts and ratios as used herein are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified.
The composition and methods of the present invention can comprise, consist of, or consist essentially of, the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in compositions intended for mammal consumption.
Method
The present invention is a method for decreasing inflammation and stress in a mammal. The method comprises administration to a mammal a composition comprising a glucose anti-metabolite or a avocado or mannoheptulose or avocado extract; and wherein the composition comprises amounts of the glucose anti-metabolite or avocado or avocado extract or mannoheptulose sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite or a avocado or avocado extract or mannoheptulose.
Composition Form
The compositions are adapted for use by mammals. The composition of the present invention is preferably administered to decreasing inflammation and stress by lowering the level of C-reactive protein in the blood of a mammal. The composition of the present invention can be a moist composition (i.e. those having a total moisture content of from about 16% to 50%, by weight of the product), and/or a wet composition (i.e. those having a total moisture content of greater than 50%, by weight of the product), and/or dry composition (i.e. those having a total moisture content of from about 0% to about 16%, by weight of the product). Unless otherwise described herein, wet composition, moist composition and/ or dry composition are not limited by their composition or method of preparation.
The composition herein can be complete and nutritionally balanced. A complete and nutritionally balanced animal food composition may be compounded to be fed as the sole ration and is capable of maintaining the life and/or promote reproduction without any additional substance being consumed, except for water.
The composition and components of the present invention are selected for consumption by an animal and are not intended for consumption by humans. Non-limiting examples of compositions include supplements for an animal, pet food, dog food, cat food, treats, biscuits, raw hide, treats, chews, fillers gravy, sauce, beverage, supplemental water, and combinations thereof.
Additionally, administration in accordance with the present invention may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
Glucose Anti-Abolite
The method of the present invention comprise administering to a mammal a composition that can comprise a glucose anti-metabolite. The glucose anti-metabolites affects the level of CRP present in the blood of a mammal by decreasing inflammation and therefore resulting in decreased CRP levels subsequent to a mammal ingesting a composition comprising glucose anti-metabolites.
The level of C-reactive protein in the blood subsequent to administration of a composition comprising a glucose anti-metabolite is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.
Nonlimiting examples of glucose anti-metabolites which are useful herein include 2-deoxy-D-glucose, 5-thio-D-glucose, 3-O-methylglucose, anhydrosugars including 1,5-anhydro-D-glucitol, 2,5-anhydro-D-glucitol, and 2,5-anhydro-D-mannitol, and mannoheptulose. Mannoheptulose is preferred for use herein.
The dose of glucose anti-metabolites given to a mammal, on a daily basis, is from about 0.1 mg/kg to about 1000 mg/kg, from about 2 mg/kg to about 100 mg/kg, from about 2 mg/kg to about 10 mg/kg, wherein (as will be commonly understood in the art) the “mg” refers to level of the component and the “kg” refers to kilograms of the mammal or from about 0.0001 gram to about 1 gram of glucose anti-metabolites per kilogram of the mammal. When glucose anti-metabolites is present in a composition, the glucose anti-metabolites is less than about 5%, or less than about 2%, or from about 0.0001% to about 0.5% of the glucose anti-metabolites, all by weight of the composition. The level of component may be determined by one of ordinary skill in the art based on a variety of factors, for example, the form of the pet food composition (e.g., whether a dry composition, moist composition, wet composition, or supplement, or any other form or mixture thereof). The ordinarily skilled artisan will be able to utilize the preferred optimal doses, and use these to determine the optimal level of component within a given pet food composition.
When the glucose anti-metabolite is mannoheptulose the dose of mannoheptulose given to a mammal, on a daily basis, is from about 0.1 mg/kg to about 1000 mg/kg, from about 1 mg/kg to about 100 mg/kg, from about 2 mg/kg to about 5 mg/kg, wherein (as will be commonly understood in the art) the “mg” refers to level of the mannoheptulose and the “kg” refers to kilograms of the mammal or from about 0.0001 gram to about 1 gram of mannoheptulose per kilogram of the mammal. When mannoheptulose is present in a composition, the mannoheptulose is less than about 5%, or less than about 2%, or from about 0.0001% to about 0.5% of the mannoheptulose, all by weight of the composition.
The level of C-reactive protein in the blood subsequent to administration of a composition comprising a mannoheptulose is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.
Avocado
The method of the present invention comprises administering to a mammal a composition that can comprise avocado. The avocado affects the level of CRP present in the blood of a mammal by decreasing inflammation and stress and therefore resulting in decreased CRP levels subsequent to a mammal ingesting a composition comprising avocado.
The level of C-reactive protein in the blood subsequent to administration of a composition comprising an avocado is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.
An avocado (also commonly referred to as alligator pear, aguacate, or palta) contains unusually enriched sources of mannoheptulose, as well as related sugars and other carbohydrates. Avocado is a sub-tropical evergreen tree fruit, growing most successfully in areas of California, Florida, Hawaii, Guatemala, Mexico, the West Indies, South Africa, and Asia.
Nonlimiting examples of species of avocado that can be used in the present invention include, for example, Persea Americana and Persea nubigena, including all cultivars within these illustrative species. Cultivars may include ‘Anaheim,’ ‘Bacon,’ ‘Creamhart,’ ‘Duke,’ ‘Fuerte,’ ‘Ganter,’ ‘Gwen,’ ‘Hass,’ ‘Jim,’ ‘Lula,’ ‘Lyon,’ ‘Mexicola,’ ‘Mexicola Grande,’ ‘Murrieta Green,’ ‘Nabal,’ ‘Pinkerton,’ ‘Queen,’ ‘Puebla,’ ‘Reed,’ ‘Rincon,’ ‘Ryan,’ ‘Spinks,’ ‘Topa Topa,’ ‘Whitsell,’ ‘Wurtz,’ and ‘Zutano.’ The fruit of the avocado is particularly preferred for use herein, which may contain the pit or wherein the pit is removed or at least partially removed. Fruit from Persea Americana is particularly preferred for use herein, as well as fruit from cultivars which produce larger fruits (e.g., about 12 ounces or more when the fruit is mature), such as Anaheim, Creamhart, Fuerte, Hass, Lula, Lyon, Murrieta Green, Nabal, Queen, Puebla, Reed, Ryan, and Spinks.
The dose of avocado given to a mammal, on a daily basis, is from about 100 mg/kg to about 200 g/kg, from about 200 mg/kg to about 20 g/kg, from about 400 mg/kg to about 10 g/kg, wherein (as will be commonly understood in the art) the “mg” or “g” refers to level of avocado and the “kg” refers to kilograms of the mammal or from about 0.001 gram to about 200 gram of avocado per kilogram of the mammal. When avocado is present in a composition, the avocado is less than about 50%, or less than about 25%, or from about 0.0001% to about 5% of the avocado, all by weight of the composition. The level of avocado may be determined by one of ordinary skill in the art based on a variety of factors, for example, the form of the composition (e.g., whether a dry composition, moist composition, wet composition, or supplement, or any other form or mixture thereof). The ordinarily skilled artisan will be able to utilize the preferred optimal doses, and use these to determine the optimal level of component within a given composition.
Advantageously, mannoheptulose or any other component may be present in the recited compositions as a component of plant matter such as avocado, or other enriched source of mannoheptulose such as alfalfa, fig, or primrose. The plant matter may include the fruit, seed (or pit), branches, leaves, or any other portion of the relevant plant or combination thereof. Additionally, plant matter from alfalfa, fig, or primrose is also reported to provide relatively high levels of mannoheptulose. Alfalfa is also referred to as Medicago sativa. Fig, or Ficus carica (including Cluster fig or Sycamore fig, for example) may also be used, as well as primrose or Primula officinalis.
The mannoheptulose or any other component can be extracted from the plant matter and or avocado to form a plant extract or component extract or avocado extract and then utilized in the composition of the present invention.
When an extract of plant matter is utilized in a composition herein, the component will be present from about 1% to about 99% of the component extract, from about 5% to about 75% of the component extract, from about 10% to about 50% of the component extract, all by weight of the extract.
When an avocado extract is utilized in a composition herein, the component will be present from about 1% to about 99% of the component extract, from about 5% to about 75% of the component extract, from about 10% to about 50% of the component extract, all by weight of the extract.
When an extract of plant matter is mannoheptulose and then utilized in a composition herein, the mannoheptulose will be present from about 1% to about 99% of mannoheptulose, from about 5% to about 75% of the mannoheptulose, from about 10% to about 50% of the mannoheptulose, all by weight of the extract.
When an extract of avocado is mannoheptulose and then utilized in a composition herein, the mannoheptulose will be present from about 1% to about 99% of mannoheptulose, from about 5% to about 75% of the mannoheptulose, from about 10% to about 50% of the mannoheptulose, all by weight of the extract.
The dose of mannoheptulose used when obtained from a plant or avocado extract that is given to a mammal, on a daily basis, is from about 0.1 mg/kg to about 1000 mg/kg, from about 2 mg/kg to about 100 mg/kg, from about 2 mg/kg to about 5 mg/kg, wherein (as will be commonly understood in the art) the “mg” or “g” refers to level of the mannoheptulose and the “kg” refers to kilograms of the mammal or from about 0.001 gram to about 1 gram of mannoheptulose per kilogram of the mammal. When mannoheptulose obtained from a plant extract or avocado extract is present in a composition, the mannoheptulose is less than about 5%, or less than about 2%, or from about 0.0001% to about 0.5% of the mannoheptulose, all by weight of the composition. The level of mannoheptulose may be determined by one of ordinary skill in the art based on a variety of factors, for example, the form of the composition (e.g., whether a dry composition, moist composition, wet composition, or supplement, or any other form or mixture thereof). The ordinarily skilled artisan will be able to utilize the preferred optimal doses, and use these to determine the optimal level of component within a given composition.
The level of C-reactive protein in the blood subsequent to administration of a composition comprising an extract of mannoheptulose obtained from plant matter or avocado extract is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.
Compositions
It is anticipated that the glucose anti-metabolite or avocado or mannoheptulose or avocado extract described in the present invention can be added to any composition adapted for administration to a mammal.
Typical formulae for compositions are well known in the art. In addition to proteinaceous and farinaceous materials, the compositions of the invention generally may include vitamins, minerals, and other additives such as flavorings, preservatives, emulsifiers and humectants. The nutritional balance, including the relative proportions of vitamins, minerals, protein, fat and carbohydrate, is determined according to dietary standards known in the veterinary and nutritional art.
Nonlimiting examples of dry compositions may optionally contain on a dry matter basis, from about 1% to about 50% crude protein, from about 0.5% to about 25% crude fat, from about 1% to about 10% supplemental fiber, all by weight of the composition. The dry composition may have a total moisture content from about 1% to about 30% moisture. Alternatively, a dry composition may contain on a dry matter basis, from about 5% to about 35% crude protein, from about 5% to about 25% crude fat, from about 2% to about 8% supplemental fiber, all by weight of the composition. The dry composition may have a total moisture content from about 2% to about 20% moisture. Alternatively, the dry composition contains on a dry matter basis, a minimum protein level of about from about 9.5% to about 35%, a minimum fat level of from about 8% to about 20%, a minimum supplemental fiber level of from about 3% to about 7%, all by weight of the composition. The dry animal composition may also have a minimum metabolizable energy level of about 3.5 Kcal/g. The dry composition may have a total moisture content from about 3% to about 10%,
Nonlimiting examples of a semi-moist composition may optionally contain on a dry matter basis, from about 0.5% to about 50% crude protein, from about 0.5% to about 25% crude fat, from about 0.5% to about 15% supplemental fiber, all by weight of the composition. The semi-moist composition may have a total moisture content from about 30% to about 50% moisture. Alternatively, the semi-moist compositions may contain on a dry matter basis, from about 5% to about 35% crude protein, from about 5% to about 25% crude fat, from about 1% to about 5% supplemental fiber, and all by weight of the composition. The semi-moist composition may have a total moisture content from about 35% to about 45% moisture. Alternatively, the semi-moist composition may have on a dry matter basis, a minimum protein level of about from about 9.5% to about 22%, a minimum fat level of from about 8% to about 13%, a minimum supplemental fiber level of from about 2% to about 3%, all by weight of the composition. The semi-moist composition may have a total moisture content from about 38% to about 42%. The semi-moist composition may also have a minimum metabolizable energy level of about 3.5 Kcal/g and from about 0.1% to about 20% ash, and from about 0.001% to about 5.0% taurine.
Nonlimiting examples of a moist composition may optionally contain on a dry matter basis, from about 0.5% to about 50% crude protein, from about 0.5% to about 25% crude fat, from about 0.01% to about 15% supplemental fiber, all by weight of the composition. The moist composition may have a total moisture content from about 50% to about 90% moisture. Alternatively, the moist compositions may contain on a dry matter basis, from about 5% to about 35% crude protein, from about 5% to about 25% crude fat, from about 0.05% to about 5% supplemental fiber, all by weight of the composition. The moist composition may have a total moisture content from about 60% to about 85% moisture. Alternatively, a moist animal composition may contain on a dry matter basis, a minimum protein level of about from about 9.5% to about 22%, a minimum fat level of from about 8% to about 13%, a minimum supplemental fiber level of from about 0.1% to about 3%, all by weight of the composition. The moist composition may have a total moisture content from about 65% to about 80%. The moist composition may also have a minimum metabolizable energy level of about 1.0 Kcal/g and from about 0.1% to about 20% ash, and from about 0.001% to about 5.0% taurine.
In one embodiment of the present invention, the composition is a composition, whether dry, moist, semi-moist or otherwise, that comprises on a dry matter basis, from about 5% to about 50%, alternatively 20% to about 50% of animal-derived ingredients, by weight of the composition. Non-limiting examples of animal-derived ingredients include chicken, beef, pork, lamb, turkey (or other animal) protein or fat, egg, fishmeal, and the like.
Where the composition is in the form of a gravy, the composition may comprise at least 10% of a broth, or stock, non-limiting examples of which include vegetable beef, chicken or ham stock. Typical gravy compositions may comprise on a dry matter basis, from about 0.5% to about 5% crude protein, and from about 2% to about 5% crude fat.
Where the composition is in the form of a supplement composition such as biscuits, chews, and other treats, the supplement may comprise, on a dry matter basis, from about 20% to about 60% protein, from about 22% to about 40% protein, by weight of the supplement composition. As another example, the supplement compositions may comprise, on a dry matter basis, from about 5% to about 35% fat, or from about 10% to about 30% fat, by weight of the supplement composition. Compositions and supplement compositions intended for use by animals such as cats or dogs are commonly known in the art.
Optional Ingredients
The composition of the present invention can further comprise a wide range of other optional ingredients.
Nonlimiting examples of additional components include animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, textured wheat protein, textured soy protein, textured lupin protein, textured vegetable protein, breading, comminuted meat, flour, comminuted pasta, water, and combinations thereof.
Nonlimiting examples of optional ingredients can include at least one vegetable. Nonlimiting examples of vegetables include carrots, peas, potatoes, cabbage, celery, beans, corn, tomatoes, broccoli, cauliflower, leeks and combinations thereof.
Also useful herein, as an optional ingredient, is a filler. The filler can be a solid, a liquid or packed air. The filler can be reversible (for example thermo-reversible including gelatin) and/or irreversible (for example thermo-irreversible including egg white). Nonlimiting examples of the filler include gravy, gel, jelly, aspic, sauce, water, air (for example including nitrogen, carbon dioxide, and atmospheric air), broth, and combinations thereof.
Nonlimiting examples of colorants include, but are not limited to, synthetic or natural colorants, and any combination thereof. When present the colorants are from about 0.0001% to about 5%, more from about 0.001% to about 1%, even more from about 0.005% to about 0.1%, on a dry matter basis, of said colorant.
Additionally, probiotic microorganisms, such as Lactobacillus or Bifidobacterium species, for example, may be added to the composition or the animal food compositions themselves.
Also useful herein, as an optional ingredient, is at least one fruit. Nonlimiting examples include tomatoes, apples, pears, peaches, cherries, apricots, plums, grapes, oranges, grapefruit, lemons, limes, cranberries, raspberries, blueberries, watermelon, cantelope, mushmellon, honeydew melon, strawberries, banana, and combinations thereof.
The composition may contain other active agents such as long chain fatty acids and zinc. Suitable long chain fatty acids include alpha-linoleic acid, gamma linolenic acid, linoleic acid, eicosapentanoic acid, and docosahexanoic acid. Fish oils are a suitable source of eicosapentanoic acids (EPA) and docosahexanoic acid (DHA). The DHA level is at least about 0.05%, alternatively at least about 0.1%, alternatively at least about 0.15% of the animal food composition, all on a dry matter basis. The EPA level is at least about 0.05%, alternatively at least about 0.1%, alternatively at least about 0.15% of the animal food composition, all on a dry matter basis.
The compositions of the present invention may further comprise a source of carbohydrate. Grains or cereals such as rice, corn, milo, sorghum, barley, wheat, and the like are illustrative sources.
The compositions may also contain other materials such as dried whey and other dairy by products.
Optional Processes for Preparing the Compositions of the Present Invention
The compositions may be prepared by any of a variety of processes including, but not limited to, optional processes described herein. Disclosed herein are optional processes for preparing the present inventive compositions. The ordinarily skilled artisan will understand, however, that the compositions are not limited by the following described processes.
A process for preparing the present compositions may comprise:
The plant matter may be any portion or whole of the plant, such as the leaves, fruit, seed or pit. In one optional process herein, the avocado is provided, and the process may commence with whole avocado fruit, including the pit or devoid (or partially devoid) of the pit. If the plant matter which is provided contains a pit, or partial pit, the pit or portion thereof may be optionally removed prior to further processing. Alfalfa, fig, or primrose may be similarly processed.
Additionally, in the production of a digested plant mixture can comprise combination of the plant matter with an aqueous solution, such as water, to assist with maceration of the plant into manageable constituents. Optionally but preferably, an enzyme having cellulose or pectin activity, or any combination thereof (such as a cellulase, hemicellulase, or pectinase) is included to assist with such maceration, including to assist with dissolution and release of carbohydrates via cell wall disruption. The utility of such an enzymatic treatment may be enhanced through heating during such maceration, such as from above ambient temperature to about 120° C., or to about 100° C., or from about 60° C. to about 120° C., or from about 60° C. to about 100° C. Agitation is further preferably utilized, typically for up to about 24 hours, but dependent upon the batch under processing. In one embodiment, the pH is controlled such to preserve enzyme activity, often in the range of pH from about 4 to about 6, preferably in the range of pH from about 5 to about 6. As such, depending upon such factors as ripeness of plant matter, quality of process aqueous solution (such as water added for process, for example), and the like, amounts of acid or base may be desirable as will be appreciated by one of ordinary skill in the art. Optionally, to assist with deactivation of the enzymes present, heating may be increased at the time of, or after, initial heating and agitation to form the digested plant mixture. Water is optionally heated to processing temperatures prior to the addition of the plant matter. Heat may be applied by a jacketed tank where low pressure steam is utilized. The digested plant mixture may result in fractions which may be separated in accordance with common techniques. For example, fractions present in the digested plant mixture may be separated by filtration to provide the carbohydrate extract as the resulting filtrate, with the filter cake being discarded. Other methods may include, but not be limited to, gravimetric, centrifugal, other filtrations, or combinations thereof.
The carbohydrate extract may then be concentrated, optionally utilizing at least one concentration method selected from the group consisting of heating, vacuum drying, evaporation, refractance window drying, freeze drying, spray drying, any other useful technique, or any combination of the foregoing. In one embodiment, at least one technique such as refractance window drying is used.
Once concentrated, the carbohydrate extract may be utilized in a composition of the present invention. In one embodiment herein, the present processes result in preferred yields of mannoheptulose or other components, based on the starting mass of the plant matter (e.g., avocado). In one embodiment, the yield of mannoheptulose present in the carbohydrate extract subsequent to concentration is less than about 20%, or from about 0.1% to about 10%, or from about 1% to about 7%, based on the starting mass of the plant matter. In another embodiment, the yield of the carbohydrate extract subsequent to concentration is less than about 30%, or from about 5% to about 25%, or from about 8% to about 20%, based on the starting mass of the plant matter. Of course, even higher yields may be desirable, and lower yields may also be acceptable.
C-Reactive Protein (CRP) Procedure
CRP analysis using Diasorin reagents (cat. No. 86083) has been adapted for use on the Hitachi 911 automated chemistry analyzer for samples. All samples are analyzed on the decreased sample size function of the Hitachi 911. Components of the Diasorin kit include polymer diluent, antibody reagent, and saline. CRP calibration standards and a human CRP control (cat. No. 86108) are used to generate a calibration curve and ensure the method is calibrated properly. The Diasorin CRP analysis is an immunopreciptin analysis. The sample and antiserum are mixed together forming insoluble complexes that produce turbidity and scatter light. The absorbance is then measured. Sample concentrations are interpolated from the calibration curve. Polymer diluent is used as is for T1 which dispenses 10 seconds after sample dispense. Antibody reagent diluted 1:7 with saline is used for T3 which dispenses 5 minutes after T1 is dispensed. The calibration type used is a full type using a blank (saline) and at least 3 programmed standards, 5 standards are used to ensure a broad range. The Diasorin kit comes with 5 standards, but we do not use the 100 standard (#5) and we dilute standard #2 1:10 with saline to increase our sensitivity range. Calibration type is Logit-Log 4P. The analysis uses a 2 point end (sample-blanked endpoint assay) with a primary wavelength of 340 nm and secondary wavelength of 700 nm. The CRP control and saline sample are analyzed with each run. After sample analysis has been completed a reaction monitor is viewed and printed for each sample. The reaction monitor allows a view in graph form of the photometric absorbance vs time. For CRPs cells are measured at 1-5, 6-10, 11-5, 16-20, 26-30, and 31-35. Cells 16-20 are compared with cells 31-35 and if cells 16-20 are higher than 31-35 a dilution must be performed (1:5 with saline) and the sample reanalyzed. Also all samples that read 0.0 upon initial analysis are diluted and reanalyzed to prevent false negative results, regardless of the cell comparisons. Results are reported in units of mg/L.
NOTE: Calibration standard values change periodically and should be put into the chemistry parameters of the Hitachi 911 when changed under the chemistry parameters menu.
Total Moisture Content Method
The method involves the analysis of the total moisture content in the composition. The analysis is based on the procedure outlined in AOAC method 930.15 and AACC method 44-19.
A composition sample is prepared by taking one unit volume, for example, 375 gram of the composition, and homogenizing in a food processor to a uniform consistency like a paste. A composition larger than 375 gram would be subdivided to create equal and representative fractions of the whole such that a 375 gram sample is obtained.
The paste of the composition is individually sampled in triplicate at a volume less than or equal to 100 ml and placed individually sealed in a 100 ml Nasco Whirl-Pak® (Fort Atkinson, Wis. 53538-0901). During the process of sealing the Whirl-Pak®, excess air is evacuated manually from the container just prior to final closure thereby minimizing the container headspace. The Whirl-Pak® is closed per manufacturer's instructions—tightly folding the bag over three (3) times and bending the tabs over 180 degrees.
All samples are refrigerated at 6° C. for less than 48 h prior to moisture analysis.
For total moisture analysis, the tare weight of each moisture tin and lid are recorded to 0.0001 g. Moisture tins and lids are handled using dry and clean forceps. Moisture tins and lids are held dry over desiccant in a sealed desiccator. A Whirl-Pak® containing a sample is unfolded and a 2.0000+/−0.2000 gram sample is weighed into the uncovered moisture tin. The weight of the sample in the moisture tin is recorded. The lid is placed atop the moisture tin in an open position to allow moisture loss but contain all other material during air oven drying. The lid and moisture tin loaded with sample are placed in an air oven operating at 135° C. for 6 h. Time is tracked using a count-down timer.
After drying, the tin is removed from the oven and the dried lid is placed atop the tin using forceps. The covered moisture tin with dried sample is placed immediately in a desiccator to cool. The sealed desiccator is filled below the stage with active desiccant. Once cool to room temperature, the covered moisture tin with dried sample is weighed to 0.0001 g and weight recorded. The total moisture content of each sample is calculated using the following formula:
Total Moisture Content(%)=100−(weight of tin, lid and sample after drying−empty tin and lid weight)×100 /initial sample weight.
The following examples further describe and demonstrate embodiments within the scope of the invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention. All of the following examples are compositions that are utilized by a mammal.
The dry compositions of Examples 1-72 can be made by first, milling and mixing the cereal grains with protein meal, egg products, vitamins and minerals and fiber sources and avocado or avocado extract or mannoheptulose or glucose anti-metabolite. Then, add the mixed, dried ingredients to the meat products and fat sources. Extrude the ingredients into kibbles. Dry the kibbles. Package the finished product.
The wet compositions of Examples 73-144 can be made by first drying and milling cereal grains. Mix dried cereal grains, Protein meals, egg product, vitamins, minerals and fiber sources and avocado or avocado extract or mannoheptulose or glucose anti-metabolite. Blend dry ingredients with meat products and fat sources. The mixture is packaged into cans and cooked via retort process to provided finished product. For preformed pieces (chunks in gravy) mixture is extruded, passed through a steam tunnel for preconditioning, cut to desired shape, packaged with added water and retorted to provide safe finished product.
It should be understood that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification includes every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification includes every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.
All parts, ratios, and percentages herein, in the Specification, Examples, and Claims, are by weight and all numerical limits are used with the normal degree of accuracy afforded by the art, unless otherwise specified.
All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
This application claims the benefit of U.S. Provisional Application No. 60/898,788, filed Feb. 1, 2007, and is a continuation-in-part application of U.S. application Ser No. 10/842,301, filed May. 10, 2004, patented on Feb. 23, 2010, as U.S. Pat. No. 7,666,459.
Number | Name | Date | Kind |
---|---|---|---|
571521 | Heberline et al. | Nov 1896 | A |
1086936 | Pounder et al. | Feb 1914 | A |
1503094 | Cramer | Jul 1924 | A |
2473773 | West | Jun 1949 | A |
2540979 | Clymer et al. | Feb 1951 | A |
2641548 | Heinrich | Jun 1953 | A |
3320130 | Henry | May 1967 | A |
3398001 | Benson | Aug 1968 | A |
3429426 | Wolf et al. | Feb 1969 | A |
3431338 | Munzel | Mar 1969 | A |
3677898 | Mitsugi | Jul 1972 | A |
3897572 | Riggs et al. | Jul 1975 | A |
3898132 | Heltrick | Aug 1975 | A |
3931885 | Nahill et al. | Jan 1976 | A |
3957974 | Hata | May 1976 | A |
3989822 | Whistler | Nov 1976 | A |
4248857 | DeNeale et al. | Feb 1981 | A |
4295567 | Knudsen et al. | Oct 1981 | A |
4314995 | Hata et al. | Feb 1982 | A |
4332790 | Sozzi et al. | Jun 1982 | A |
4338346 | Brand | Jul 1982 | A |
4399163 | Brennan et al. | Aug 1983 | A |
4403623 | Mark | Sep 1983 | A |
4411925 | Brennan et al. | Oct 1983 | A |
4423029 | Rizzi | Dec 1983 | A |
4434231 | Jung | Feb 1984 | A |
4518696 | Gehrman et al. | May 1985 | A |
4592748 | Jost | Jun 1986 | A |
4647453 | Meismer | Mar 1987 | A |
4736849 | Leonard et al. | Apr 1988 | A |
4764389 | LaBarge | Aug 1988 | A |
4767623 | Conway et al. | Aug 1988 | A |
4781939 | Martin et al. | Nov 1988 | A |
4786507 | Schmidt | Nov 1988 | A |
4797289 | Reddy | Jan 1989 | A |
4806368 | Reddy | Feb 1989 | A |
4808626 | Friedman | Feb 1989 | A |
4814193 | Shenouda | Mar 1989 | A |
4816259 | Matthews et al. | Mar 1989 | A |
4859377 | Shasha et al. | Aug 1989 | A |
4889238 | Batchelor | Dec 1989 | A |
4935247 | Martila et al. | Jun 1990 | A |
4937077 | Deetz, III | Jun 1990 | A |
5032399 | Gorbach et al. | Jul 1991 | A |
5096717 | Wirth et al. | Mar 1992 | A |
5132137 | Reimann | Jul 1992 | A |
5160745 | DeLuca et al. | Nov 1992 | A |
5171580 | Imartino et al. | Dec 1992 | A |
5176911 | Tosi et al. | Jan 1993 | A |
5286495 | Batich et al. | Feb 1994 | A |
5292657 | Rutherford | Mar 1994 | A |
5296233 | Batista et al. | Mar 1994 | A |
5322686 | Grahn et al. | Jun 1994 | A |
5344824 | Ohkuma | Sep 1994 | A |
5389389 | Beck | Feb 1995 | A |
5413960 | Dobrogosz et al. | May 1995 | A |
5445828 | Pozzi et al. | Aug 1995 | A |
5451400 | Stern et al. | Sep 1995 | A |
5474932 | Bengmark et al. | Dec 1995 | A |
5484721 | Ors et al. | Jan 1996 | A |
5501857 | Zimmer | Mar 1996 | A |
5501868 | Collings | Mar 1996 | A |
5516684 | Saito et al. | May 1996 | A |
5518733 | Lamothe et al. | May 1996 | A |
5531988 | Paul | Jul 1996 | A |
5538743 | Heinemann et al. | Jul 1996 | A |
5540945 | Ikushima | Jul 1996 | A |
5569634 | Miller et al. | Oct 1996 | A |
5578302 | Brassart et al. | Nov 1996 | A |
5582643 | Takei et al. | Dec 1996 | A |
5603930 | Brassart | Feb 1997 | A |
5629017 | Pozzi et al. | May 1997 | A |
5633012 | Ford | May 1997 | A |
5645830 | Reid | Jul 1997 | A |
5698437 | Matsuda et al. | Dec 1997 | A |
5726161 | Whistler | Mar 1998 | A |
5728380 | Allen et al. | Mar 1998 | A |
5733540 | Lee | Mar 1998 | A |
5756088 | Matsuura et al. | May 1998 | A |
5766520 | Bronshtein | Jun 1998 | A |
5785990 | Langrehr | Jul 1998 | A |
5814338 | Veronesi | Sep 1998 | A |
5824779 | Koegel et al. | Oct 1998 | A |
5849327 | Berliner et al. | Dec 1998 | A |
5853697 | Strober et al. | Dec 1998 | A |
5854067 | Newgard et al. | Dec 1998 | A |
5858356 | Wolf et al. | Jan 1999 | A |
5871794 | Brito | Feb 1999 | A |
5871802 | Gao | Feb 1999 | A |
5894029 | Brown et al. | Apr 1999 | A |
5910447 | Lawrence et al. | Jun 1999 | A |
5939117 | Chen | Aug 1999 | A |
5952021 | Santus | Sep 1999 | A |
5952033 | Anantharaman et al. | Sep 1999 | A |
5962043 | Jones | Oct 1999 | A |
5968569 | Cavadini et al. | Oct 1999 | A |
5976579 | McLean | Nov 1999 | A |
6007808 | DeHaen et al. | Dec 1999 | A |
6010725 | Meister et al. | Jan 2000 | A |
6033888 | Batich et al. | Mar 2000 | A |
6042857 | Jones et al. | Mar 2000 | A |
6063414 | Jones et al. | May 2000 | A |
6077530 | Weinstein et al. | Jun 2000 | A |
6080401 | Reddy et al. | Jun 2000 | A |
6083520 | Toneby | Jul 2000 | A |
6117477 | Paluch et al. | Sep 2000 | A |
6133323 | Hayek | Oct 2000 | A |
6156355 | Shields et al. | Dec 2000 | A |
6190591 | van Lengerich | Feb 2001 | B1 |
6254886 | Fusca et al. | Jul 2001 | B1 |
6277370 | Vavaliere Ved. Vesely et al. | Aug 2001 | B1 |
6309666 | Hatano et al. | Oct 2001 | B1 |
6310090 | Hayek | Oct 2001 | B1 |
6355242 | Allison et al. | Mar 2002 | B1 |
6358555 | Takahashi | Mar 2002 | B1 |
6365148 | Kim et al. | Apr 2002 | B1 |
6375956 | Hermelin et al. | Apr 2002 | B1 |
6394803 | Salz et al. | May 2002 | B1 |
6406853 | Spindler | Jun 2002 | B1 |
6451341 | Slaga et al. | Sep 2002 | B1 |
6500463 | van Lengerich | Dec 2002 | B1 |
6506389 | Leer et al. | Jan 2003 | B2 |
6544568 | La Droitte et al. | Apr 2003 | B2 |
6586027 | Axelrod | Jul 2003 | B2 |
6588180 | Heath | Jul 2003 | B2 |
6592863 | Fuchs et al. | Jul 2003 | B2 |
6596946 | Yagi et al. | Jul 2003 | B2 |
6607905 | Luquet | Aug 2003 | B1 |
6620440 | Hsia | Sep 2003 | B1 |
6624162 | Uchida et al. | Sep 2003 | B2 |
6681935 | Lewis | Jan 2004 | B1 |
6713083 | McGregor et al. | Mar 2004 | B1 |
6723358 | van Lengerich | Apr 2004 | B1 |
6737089 | Wadsworth | May 2004 | B2 |
6746672 | O'Sullivan | Jun 2004 | B2 |
6767573 | Dixon et al. | Jul 2004 | B1 |
6780433 | Cochran et al. | Aug 2004 | B2 |
6797266 | Naidu | Sep 2004 | B2 |
6802422 | Kalvelage et al. | Oct 2004 | B2 |
6827957 | Paluch et al. | Dec 2004 | B2 |
6835397 | Lee et al. | Dec 2004 | B2 |
6893662 | Dittmar et al. | May 2005 | B2 |
6905679 | Schiffrin et al. | Jun 2005 | B1 |
6911217 | Gren et al. | Jun 2005 | B1 |
6932990 | Konishi | Aug 2005 | B2 |
6939560 | Shen et al. | Sep 2005 | B2 |
6974594 | Ko et al. | Dec 2005 | B2 |
6979675 | Tidmarsh | Dec 2005 | B2 |
6991819 | Pannevis et al. | Jan 2006 | B2 |
7008648 | Corley et al. | Mar 2006 | B2 |
7037708 | Runge et al. | May 2006 | B1 |
7081478 | Hauptmann et al. | Jul 2006 | B2 |
7097831 | Bengs | Aug 2006 | B1 |
7115297 | Stillman et al. | Oct 2006 | B2 |
7122370 | Porubcan | Oct 2006 | B2 |
RE39436 | Spindler et al. | Dec 2006 | E |
7150986 | Kato et al. | Dec 2006 | B2 |
7179460 | Dennin et al. | Feb 2007 | B2 |
7186545 | Collins et al. | Mar 2007 | B2 |
7189390 | Zink et al. | Mar 2007 | B2 |
7195906 | Collins et al. | Mar 2007 | B2 |
7201923 | van Lengerich et al. | Apr 2007 | B1 |
7229818 | Porubcan | Jun 2007 | B2 |
7235276 | Allen et al. | Jun 2007 | B2 |
7235395 | Stadler et al. | Jun 2007 | B2 |
7381406 | Zink et al. | Jun 2008 | B2 |
7390519 | Collins et al. | Jun 2008 | B2 |
7427398 | Baillon et al. | Sep 2008 | B2 |
7498162 | Germond et al. | Mar 2009 | B2 |
7544497 | Sinclair et al. | Jun 2009 | B2 |
7547527 | Baur et al. | Jun 2009 | B2 |
7550285 | Schiffrin et al. | Jun 2009 | B2 |
7579030 | Domingues et al. | Aug 2009 | B2 |
7647098 | Prichep | Jan 2010 | B2 |
7674808 | Bueno Calderon et al. | Mar 2010 | B2 |
7687077 | Khoo | Mar 2010 | B2 |
7687085 | Hayashi et al. | Mar 2010 | B2 |
7700141 | Baillon et al. | Apr 2010 | B2 |
7700315 | Arigoni et al. | Apr 2010 | B2 |
7771982 | Zink et al. | Aug 2010 | B2 |
7785635 | Boileau et al. | Aug 2010 | B1 |
7833554 | Piccirilli et al. | Nov 2010 | B2 |
7838057 | Schmidt et al. | Nov 2010 | B2 |
7842329 | Saylock et al. | Nov 2010 | B2 |
7906112 | Boileau et al. | Mar 2011 | B2 |
7910144 | Ballevre et al. | Mar 2011 | B2 |
7935334 | Lin | May 2011 | B2 |
7960605 | Zhao-Wilson | Jun 2011 | B2 |
7998473 | Boileau et al. | Aug 2011 | B2 |
8030279 | Joullie | Oct 2011 | B2 |
8034601 | Boileau et al. | Oct 2011 | B2 |
8057840 | Harrison et al. | Nov 2011 | B2 |
8092608 | Rochat et al. | Jan 2012 | B2 |
8101170 | Plail et al. | Jan 2012 | B2 |
8142810 | Sunvold | Mar 2012 | B2 |
8263146 | Bengtsson et al. | Sep 2012 | B2 |
8313757 | Van Lengerich | Nov 2012 | B2 |
8329190 | Vidal et al. | Dec 2012 | B2 |
8394370 | Garcia | Mar 2013 | B2 |
8486389 | Sidhu et al. | Jul 2013 | B2 |
8524304 | Prakash et al. | Sep 2013 | B2 |
8540980 | London et al. | Sep 2013 | B2 |
8557764 | Newell et al. | Oct 2013 | B2 |
8563522 | Pitha et al. | Oct 2013 | B2 |
8637495 | Waldron et al. | Jan 2014 | B2 |
8663729 | Hayek et al. | Mar 2014 | B2 |
8691303 | Sunvold et al. | Apr 2014 | B2 |
8722112 | Zicker et al. | May 2014 | B2 |
8728559 | Hayek et al. | May 2014 | B2 |
8771675 | Zink et al. | Jul 2014 | B2 |
8802158 | Boileau et al. | Aug 2014 | B2 |
8802179 | Miller | Aug 2014 | B2 |
8808770 | Henderson et al. | Aug 2014 | B2 |
8809035 | Boileau et al. | Aug 2014 | B2 |
8865197 | Tandler et al. | Oct 2014 | B2 |
8877178 | Boileau et al. | Nov 2014 | B2 |
8894991 | Boileau et al. | Nov 2014 | B2 |
8900569 | Boileau et al. | Dec 2014 | B2 |
8916145 | Mercenier et al. | Dec 2014 | B2 |
8962007 | Perez et al. | Feb 2015 | B2 |
9089576 | Piccirilli et al. | Jul 2015 | B2 |
9119843 | Chen et al. | Sep 2015 | B2 |
9192177 | Boileau et al. | Nov 2015 | B2 |
20020022019 | Laulund | Feb 2002 | A1 |
20020035071 | Pitha et al. | Mar 2002 | A1 |
20020119237 | Hevey | Aug 2002 | A1 |
20030049240 | Ballevre et al. | Mar 2003 | A1 |
20030060503 | Hamilton | Mar 2003 | A1 |
20030092669 | Chapnick | May 2003 | A1 |
20030104090 | Levy et al. | Jun 2003 | A1 |
20030113306 | Collins et al. | Jun 2003 | A1 |
20030143293 | Shushunov | Jul 2003 | A1 |
20030157166 | Chen | Aug 2003 | A1 |
20030170217 | Collins et al. | Sep 2003 | A1 |
20030170355 | Glazier et al. | Sep 2003 | A1 |
20030190314 | Campbell et al. | Oct 2003 | A1 |
20030194423 | Torney et al. | Oct 2003 | A1 |
20040001817 | Giampapa et al. | Jan 2004 | A1 |
20040022882 | Picirilli | Feb 2004 | A1 |
20040047896 | Malnoe et al. | Mar 2004 | A1 |
20040161422 | Ranganathan | Aug 2004 | A1 |
20040167229 | Bakker-Arkema et al. | Aug 2004 | A1 |
20040228933 | Chapnick | Nov 2004 | A1 |
20040234579 | Finke | Nov 2004 | A1 |
20040253357 | De Zarate | Dec 2004 | A1 |
20040265279 | Dinan et al. | Dec 2004 | A1 |
20050013849 | Lemaure | Jan 2005 | A1 |
20050074519 | Bartnick et al. | Apr 2005 | A1 |
20050079244 | Giffard et al. | Apr 2005 | A1 |
20050084479 | Corthesy et al. | Apr 2005 | A1 |
20050100617 | Malnoe et al. | May 2005 | A1 |
20050106131 | Breton et al. | May 2005 | A1 |
20050112259 | Qvyjt | May 2005 | A1 |
20050152884 | Boileau et al. | Jul 2005 | A1 |
20050153018 | Ubbink et al. | Jul 2005 | A1 |
20050164978 | Chapnick et al. | Jul 2005 | A1 |
20050180961 | Pecquet et al. | Aug 2005 | A1 |
20050208163 | Brovelli et al. | Sep 2005 | A1 |
20050249837 | Massimino et al. | Nov 2005 | A1 |
20050249841 | Hayek et al. | Nov 2005 | A1 |
20050266438 | Spindler | Dec 2005 | A1 |
20050281910 | Schiffrin et al. | Dec 2005 | A1 |
20060002909 | Takeda | Jan 2006 | A1 |
20060008511 | Lin et al. | Jan 2006 | A1 |
20060070895 | Khawaja | Apr 2006 | A1 |
20060088517 | Kriegler | Apr 2006 | A1 |
20060099196 | Breton et al. | May 2006 | A1 |
20060100162 | Pitha et al. | May 2006 | A1 |
20060116330 | Pitha | Jun 2006 | A1 |
20060121015 | Collins et al. | Jun 2006 | A1 |
20060147962 | Jones et al. | Jul 2006 | A1 |
20060165670 | Berr et al. | Jul 2006 | A1 |
20060228448 | Boileau et al. | Oct 2006 | A1 |
20060228459 | Tribelhorn et al. | Oct 2006 | A1 |
20060263416 | Brent, Jr. | Nov 2006 | A1 |
20070009577 | Mankovitz | Jan 2007 | A1 |
20070031441 | Collins et al. | Feb 2007 | A1 |
20070082107 | Aimutis et al. | Apr 2007 | A1 |
20070098744 | Knorr et al. | May 2007 | A1 |
20070116853 | Krohn et al. | May 2007 | A1 |
20070122531 | Considini | May 2007 | A1 |
20070123460 | Chang et al. | May 2007 | A1 |
20070129428 | Richelle et al. | Jun 2007 | A1 |
20070149466 | Milburn et al. | Jun 2007 | A1 |
20070160589 | Mattson et al. | Jul 2007 | A1 |
20070166295 | Schildgen et al. | Jul 2007 | A1 |
20070178078 | Khoo | Aug 2007 | A1 |
20070190171 | Yamka et al. | Aug 2007 | A1 |
20070218164 | Stojanovic | Sep 2007 | A1 |
20070231371 | Pan et al. | Oct 2007 | A1 |
20070231414 | Aoki et al. | Oct 2007 | A1 |
20070269515 | Henriksen et al. | Nov 2007 | A1 |
20070269553 | Le et al. | Nov 2007 | A1 |
20070280964 | Knorr et al. | Dec 2007 | A1 |
20070286935 | Grigorov et al. | Dec 2007 | A1 |
20080044481 | Harel | Feb 2008 | A1 |
20080050354 | Garault et al. | Feb 2008 | A1 |
20080050355 | Vaslin | Feb 2008 | A1 |
20080053490 | Clark et al. | Mar 2008 | A1 |
20080107699 | Spigelman et al. | May 2008 | A1 |
20080145341 | Myatt et al. | Jun 2008 | A1 |
20080214479 | Pitha | Sep 2008 | A1 |
20080241226 | Abeln et al. | Oct 2008 | A1 |
20080260696 | Massimino et al. | Oct 2008 | A1 |
20080260866 | Massimino et al. | Oct 2008 | A1 |
20080279786 | Cash | Nov 2008 | A1 |
20080280274 | Freisen et al. | Nov 2008 | A1 |
20080305210 | Petersen | Dec 2008 | A1 |
20080311226 | Yamka et al. | Dec 2008 | A1 |
20080317905 | Yamka et al. | Dec 2008 | A1 |
20090252834 | Hayek et al. | Oct 2009 | A1 |
20090263542 | Lin et al. | Oct 2009 | A1 |
20090274796 | Yamka et al. | Nov 2009 | A1 |
20090324761 | Khoo et al. | Dec 2009 | A1 |
20100003369 | Ter Haar et al. | Jan 2010 | A1 |
20100112003 | Collins et al. | May 2010 | A1 |
20100150870 | Young et al. | Jun 2010 | A1 |
20100203225 | Kerr et al. | Aug 2010 | A1 |
20100233320 | Sunvold et al. | Sep 2010 | A1 |
20100316769 | Czarnecki-Maulden et al. | Dec 2010 | A1 |
20110117068 | Lang et al. | May 2011 | A1 |
20110274676 | Farmer et al. | Nov 2011 | A1 |
20120115798 | Massimino et al. | May 2012 | A1 |
20120282373 | Luhadiya et al. | Nov 2012 | A1 |
20120283197 | Luhadiya et al. | Nov 2012 | A1 |
20130183255 | Saunois et al. | Jul 2013 | A1 |
20140274920 | Davenport | Sep 2014 | A1 |
20140348975 | Davenport et al. | Nov 2014 | A1 |
20140348986 | Beyer et al. | Nov 2014 | A1 |
20140349002 | Beyer | Nov 2014 | A1 |
20150132420 | Villagran et al. | May 2015 | A1 |
20150208679 | Mir et al. | Jul 2015 | A1 |
Number | Date | Country |
---|---|---|
199642145 | Aug 1996 | AU |
199928098 | Jul 1999 | AU |
1300538 | May 1992 | CA |
2093287 | Oct 1993 | CA |
2256256 | Jun 2000 | CA |
2569249 | Nov 2005 | CA |
3715070 | Nov 1988 | DE |
4018392 | Dec 1991 | DE |
10217970 | Nov 2003 | DE |
0168112 | Jan 1986 | EP |
0181170 | May 1986 | EP |
0212746 | Mar 1987 | EP |
0212747 | Mar 1987 | EP |
0298605 | Jan 1989 | EP |
0391416 | Oct 1990 | EP |
0399819 | Nov 1990 | EP |
0563934 | Oct 1993 | EP |
0627173 | Dec 1994 | EP |
0850569 | Jul 1998 | EP |
1547466 | Jun 2005 | EP |
1637041 | Mar 2006 | EP |
1806056 | Jul 2007 | EP |
1806057 | Jul 2007 | EP |
2615203 | Nov 1988 | FR |
2663198 | Dec 1991 | FR |
1190387 | May 1970 | GB |
1503094 | Mar 1978 | GB |
1595054 | Aug 1981 | GB |
2241421 | Sep 1990 | GB |
2252228 | Aug 1992 | GB |
S59213368 | Dec 1984 | JP |
S6024153 | Feb 1985 | JP |
S6297221 | May 1987 | JP |
S62201823 | Sep 1987 | JP |
03076561 | Apr 1991 | JP |
H06256170 | Sep 1994 | JP |
H08242763 | Sep 1996 | JP |
2000191519 | Jul 2000 | JP |
2001278781 | Oct 2001 | JP |
2001309753 | Nov 2001 | JP |
2007117083 | Nov 2001 | JP |
1995378530 | Aug 2003 | JP |
2004173675 | Jun 2004 | JP |
2006055145 | Mar 2006 | JP |
20020050048 | Jun 2002 | KR |
20040024774 | Mar 2004 | KR |
2086248 | Aug 1997 | RU |
2123343 | Dec 1998 | RU |
2388320 | May 2010 | RU |
2407401 | Dec 2010 | RU |
8808452 | Nov 1988 | WO |
8905849 | Jun 1989 | WO |
9001335 | Feb 1990 | WO |
9117672 | Nov 1991 | WO |
9302558 | Feb 1993 | WO |
9404180 | Mar 1994 | WO |
9421284 | Sep 1994 | WO |
9503809 | Feb 1995 | WO |
9507090 | Mar 1995 | WO |
9709448 | Mar 1997 | WO |
9716198 | May 1997 | WO |
9720577 | Jun 1997 | WO |
9819668 | May 1998 | WO |
9827967 | Jul 1998 | WO |
9854982 | Dec 1998 | WO |
9909839 | Mar 1999 | WO |
9930576 | Jun 1999 | WO |
9952511 | Oct 1999 | WO |
WO 9951108 | Oct 1999 | WO |
0006127 | Feb 2000 | WO |
0112164 | Feb 2001 | WO |
0190311 | Nov 2001 | WO |
03045356 | Jun 2003 | WO |
03075676 | Sep 2003 | WO |
2004074496 | Sep 2004 | WO |
WO 2004100670 | Nov 2004 | WO |
WO 2005115421 | Apr 2005 | WO |
2005070232 | Aug 2005 | WO |
2005092116 | Oct 2005 | WO |
WO 2005105123 | Nov 2005 | WO |
2007060539 | May 2007 | WO |
WO 2007057439 | May 2007 | WO |
2007126990 | Nov 2007 | WO |
2007137808 | Dec 2007 | WO |
Entry |
---|
Adeyemi et al, Analgesic and anti-inflammatory effects of the aqueous extract of leaves of Persea Americana Mill (lauraceae), Fitoterapia 73 (2002) 375-380. |
Nordal et al, Isolation of mannoheptulose and identification of its phosphate in avocado leaves, Meddelelser fra Norsk Farmaceutisk Selskap (1955), 17, 207-13. |
Wan et al, Dietary supplementation with 2-deoxy-d-glucose improves cardiovascular and neuroendocrine stress adaptation in rats; Am. J. Physiol Heart Circ. Physiol; Bearing dates of Oct. 10, 2003. |
Ojewole et al, Anticonvulsant effect of Persea americana Mill (Lauraceae) (Avocado) leaf aqueous extract in mice. Phytotherapy research : PTR, (Aug. 2006) vol. 20, No. 8, pp. 696-700. |
Appelboom, Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scandinavian journal of rheumatology, (2001) vol. 30, No. 4, pp. 242-247. |
Adeyemi et al, “Analgesic and Anti-Inflammatory Effects of the Aqueous Extract Leaves of Persea Americana Mill (Lauraceae)” Fitoterapia, IDB Holding, Milan, IT, vol. 73, No. 5, Aug. 1, 2002, pp. 375-380, XP002318086. |
“Avocado sugars are effective inducer of cutaneous defensive functions” Journal of the American Academy of Dermatology, C V Mosby, St Louis MO, US, vol. 50, No. 2, Feb. 1, 2007 p. AB84, XP005937005. |
Burger et al., “Cardiomyopathy in Ostriches (Struthio Camelus) Due to Avocado 9Persea americana Var. guatemalensis) Intoxication”, Journal of the South African Veterinary Association, vol. Jaargang 65 No. 2, Jun./Jun. 1994. |
Byung Pal Yu et al., “Modulation of Aging Processes by Dietary Restriction”, CRC Press, Boca Raton (1994). |
Cullen et al. , “Inhibition of glucose metabolism in pancreatic cancer induces cytotoxicity via metabolic oxidative stress” Gastroenterology, vol. 128, No. 4 supp. 2, Apr. 2005 pp. A483, XP002495963. |
Database Embase (Online) Elsevier Science Publishers, Amsterdam, NL, Nov. 2004, Carranza J et al, “Lower quantities of avocado as daily source of monounsaturated fats: Effect on serum and membrane lipids, endothelial function, platelet aggregation and C-reactive protein in patients with metabolic syndrome” XP002485347. |
Ekor et al., “Protective effect of the methanolic leaf extract of Persea anericana (avocado) against paracetamol-induced acute hepatotoxicity in rats” International Jornal of Pharmacology, Asian Network for Scientific Information, vol. 2, No. 4, Jan. 1, 2006, pp. 416-420, XP001538905. |
F. B. La Forge, Absorption and Effect of Ingested Mannoheptulose, Nutrition Reviews, vol. 27, No. 7 1969. |
Facchini et al., Insulin Resistance as a Predictor of Age-Related Diseases, The Journal of Clinical Endocrinology & Metabolism, 86(8): 3574-3578 , 2001. |
Francesconi et al., “5-Thio-D-Glucose: Hypothermic Responses in Mice”, Am. J. Physiology, 239(3) R214-R218, 1980. |
Guo et al. , “In Vivo 2-Deoxyglucose Administration Preserves Glucose and Glutamate Transport and Mitochondrial Function in Cortical Synaptic Terminals After Exposure to Amyloid Beta-Peptide and Iron: Evidence for a Stress Response” Experimental Neurology, Academic Press, vol. 166. No. 1, Jan. 1, 2000, XP008056810 pp. 173-179. |
Kalant et al., “Effect of Diet Restriction on Glucose Metabolism and Insulin Responsiveness in Aging Rats”, Mechanisms of Ageing and Development, 46 (1988) 89-104. |
Kealy et al., “Effects of Diet Restriction on Life Span and Age-Related Changes in Dogs”, JAVMA, vol. 220, No. 9, May 1, 2002. |
Koizumi et al., “Influences of Dietary Restriction and Age on Liver Enzyme Activities and Lipid Peroxidation in Mice” 1987 American Institute of Nutrition, Jul. 1986. |
Kurata et al., “Structural Evaluation of Glucose Analogues on Feeding Elicitation in Rat”, Metabolism, vol. 38, No. 1 (Jan.), 1989: pp. 46-51. |
Lane et al., “2-Deoxy-D-Glucose Feeding in Rats Mimics Physiologic Effects of Calorie Restriction”, Journal of Anti-Aging Medicine, vol. 1, No. 4, 1998. |
Lane et al., “Calorie Restriction in Nonhuman Primates: Implications for Age-Related Disease Risk”, Journal of Anti-Aging Medicine, vol. 1, No. 4, 1998. |
Lane et al., “Calorie Restriction Lowers Body Temperature in Rhesus Monkeys, Consistent With a Postulated Anti-Aging Mechanism in Rodents”, Proc. Natl. Acad. Sci., vol. 93 pp. 4159-4164, Apr. 1996. |
Lawrence Fishbein et al., Biological Effects of Dietary Restriction, Springer-Verlag, 1991. |
Liu et al., “‘Hass’ Avocado Carbohydrate Fluctuations. I. Growth and Phenology”, J. Amer. Soc. Hort. Sci. 124(6): 671-675. 1999. |
Liu et al., “‘Hass’ Avocado Carbohydrate Fluctuations. II. Fruit Growth and Ripening”, J. Amer. Soc. Hort. Sci., 124(6): 676-681. 1999. |
Liu et al., “Postulated Physiological Roles of the Seven-Carbon Sugars, Mannoheptulose, and Perseitol in Avocado”, J. Amer. Soc. Hort. Sci., 127 (1): 108-114, 2002. |
Masoro et al., “Dietary Restriction Alters Characteristics of Glucose Fuel Use”, Journal of Geronotology, Biological Sciences 1992, vol. 47, No. 6 B202-B208. |
McKay et al., “The Effect of Retarded Growth Upon the Length of Life Span and Upon the Ultimate Body Size”, J. Nutr., vol. 10, pp. 63-79 (1935). |
Meyer et al., “Effects of D-mannoheptulose and Its Hexaacetate Ester on Hormonal Secretion From the Perfused Pancreas”, International Journal of Molecular Medicine, 6: 143-152, 2000. |
Naveh et al., “Defatted Avocado Pulp Reduces Body Weight and Total Hepatic Fat but Increases Plasma Cholesterol in Male Rats Fed Diets wWth Cholesterol”, American Society for Nutritional Sciences, 2002, pp. 2015-2018. |
Nutrigenomics New Zealand Sutton et al, “Considerations for successful development and launch of personalized nutrigenomic foods” Mutation Research, Amsterdam, NL, vol. 622. No. 1-2, Aug. 8, 2007, pp. 117-121, XP022191854. |
Poehlman et al., “Caloric Restriction Mimetics: Physical Activity and Body Composition Changes”, Journals of Geronotology: Series A 2001, vol. 56A (Special Issue I): 45-54. |
Ramsey et al., “Dietary Restriction and Aging in Rehesus Monkeys: The University of Wisconsin Study”, Experimental Gerontology, 35 (2000) 1131-1149. |
Rezek et al., “Glucose Antimetabolites and Hunger”, 106: 143-157, 1975. |
Roth et al., “Caloric Restriction in Primates and Relevance to Humans”, Laboratory of Neurosciences, Geronotology Research Center, National Institute on Aging, National Institutes of Health Pages, 307-315, 2001. |
Scarbrough et al. “2-deoxy-D-glucose and 17-(allylamino)-17-demethoxygeldanamycin enhances toxicity as well as increases parameters indicative od oxidative stress” Free Radical Biology and Medicine, Elsevier Science, vol. 43, No. suppl. 1, Nov. 14, 2007, p. S59, XP009105389. |
Sener et al., “D-mannoheptulose Uptake and Its Metabolic and Secretory Effects in Human Pancreatic Islets”, International Journal of Molecular Medicine, 6: 617-620, 2000. |
Shaw et al., “High Performance Liquid Chromatographic Analysis of d-manno-Heptulose, Perseitol, Glucose, and Fructose in Avocado Cultivars”, J. Agric. Food Chem. 1980, 28, 379-382. |
Simons et al. “2-deoxy-D-gulcose (2DG) enhances cispalatin cytotoxicity in human head and neck cancer cells via metabolic oxidative stress” Free Radical Biology and Medicine, vol. 41, No. suppl. 1, Nov. 15, 2006, pp. S112-S-113, XP009105143. |
Sakata et al., “Feeding Modulation by Pentose and Hexose Analogues1-3”, Am. J. Clin Nutr 1992: 55:272S-7S. |
Viktora, et al., “Effect of Ingested Mannopheptulose in Animals and Man”, Metabolism, 1969, vol. 18, No. 2, pp. 87-102. |
Weindruch et al., “The Retardation of Aging and Disease by Dietary Restriction”, Charles S. Thomas (1988). |
International Search Report received in connection with PCT/IB2008/050382, mailed on Oct. 7, 2008. |
A. Nordal, et al., “Isolation of Mannoheptulose and Identification of its Phosphate in Avocado Leaves”, J. Am. Chem. Soc., vol. 76, No. 20, pp. 5054-5055, 1954. |
Ridker et al., “C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-up of 14,719 Initially Healthy American Women”, Circulation, vol. 107, No. 3, pp. 391-397, Jan. 2003. |
Roe et al., “The Utilization of D-mannoheptulose (d-manno-ketoheptose) by Adult Rabbits”, Biol. Chem., vol. 112, pp. 443-449, 1936. |
Blatherwick et al., “Metabolism of D-mannoheptulose. Excretion of the Sugar After Eating Avocado”, J. Biol. Chem., vol. 133, pp. 643-650, 1940. |
Koh et al., “Effects of Mannoheptulose on Lipid Metabolism of Rats”, J. Nutr., vol. 104, pp. 1227-1233, 1974. |
Issekutz, Jr. et al., “Effect of Mannoheptulose on Glucose Kinetics in Normal and Glucocorticoid Treated Dogs”, Life Sciences, vol. 16, pp. 635-643, 1977. |
Archived pages from HTTP://web.archive.org for http://medtechnologies.com dated Jan. 2003. |
Archived pages from HTTP://web.archive.org for http://medtechnologies.com dated Feb. 2003. |
Blue Buffalo Life Protection Formula—package.pdf, http//www.bluebuff.com/products/dogs/lp-adult-chick.shtml Information accessed Feb. 3, 2009. |
Breeders Choice, AvoDERM product brochures http://www.breeders-choice.com/about/brochures.htm, Information accessed Feb. 3, 2009. |
Natures Logic Natural Chicken Dinner Fare FROZEN—package.pdf http://www.natureslogic.com/products/dp—rf—chi.html, Information accessed Feb. 3, 2009. |
Natures Logic Natural Chicken Meal—package.pdf http://www.natureslogic.com/products/dp—dry—chi.html, Information accessed Feb. 3, 2009. |
Publication downloaded from http://en.wikipedia.org/wiki/Noni on May 4, 2009, 9 pages. |
Ashcroft, et al., “Glucose Metabolism in Mouse Pancreatic Islets”, Biochem. J. (1970), 118, pp. 143-154. |
Au, et al., “Avocado Soybean Unsaponifiables (ASU) suppress TNF-a, IL-lb, cox-2, iNOS Gene Expression, and Prostaglanding E2 and Nitric Ocide Production in Articular Chondrocytes and Monocyte/Macrophages”, Osteoarthritis and Cartilage, 2007, 15, 18 pages. |
Balkau, et al., Diabetes Obes. Metab., 1 (Suppl. 1), pp. S23-31, 1999. |
Barge, “Avocados May Help Prevent Oral Cancer, OSU Study Shows”, Journal of Dental Hygiene, vol. 82, No. 2, Apr. 2008, 3 pp. |
Board, et al., “High KM Glucose Phosphorylating (Glucokinase) Activities in a Range of Tumor Cell Lines and Inhibition of Rates of Tumor Growth by the Specific Enzyme Inhibitor Mannoheptulose”, Cancer Research, vol. 55, pp. 3278-3285, Aug. 1995. |
Brai, et al., “Hypoglycemic and Hypochloesterolemic Potential of Persea Americana Leaf Extracts”, J. Med. Food, 2007, pp. 356-360. |
Brown, et al., “Glucose Phosphorylation is Essential for the Turnover of Neutral Lipid and the Second Stage Assembly of Triacylglycerol-Rich ApoB-Containing Lipoproteins in Primary Hepatocyte Cultures”, American Heart Association, Inc., 1999, pp. 321-329. |
Chan, et al., “Ultra Structural and Secretory Heterogeneity of fa/fa (Zucker) Rat Islets”, Molecular and Cellular Endocrinology, 136, 1998, pp. 119-129. |
Conde, et al., “OeMST2 Encodes a monosaccharid Transporter Expressed throughout Olive Fruit Maturation”, Plant Cell Physiol, 48(9), pp. 1299-1308, 2007. |
Ernst, “Avocado-Soybean Unsaponifiables (ASU) for Osteoarthritis-A systemic Review”, Clin. Rheumatol., 2003, 22, pp. 285-288. |
Frech, et al., “The Utility of Nutraceuticals in teh Treatment of Osteoarthritis”, Current Rheumatology Reports, 2007, 9, pp. 25-30. |
Gallagher, et al., “The Effects of Traditional Antidiabetic Plants on In Vitro Glucose Diffusion”, Nutrition Research, 23 (2003), pp. 413-424. |
Gondwe, “Effects of Oersea Americana Mill (Lauraceae) Ethanolic Leaf Extract on Blood Glucose and Kidney Function in Streptozotocin-Induced Diabetic Rats and on Kidney Cell Lines of the Proximal (LLC-PK1) and Distal Tubules (MDBK)”, Methods Find Exp Clin. Pharmacol., 2008, 30(1), pp. 25-35. |
Henrotin, et al., “Pharmaceutical and Nutraceutical Management of Canine Osteoarthritis: Present and Future Perspectives”, The Veterinary Journal, 170 (2005), pp. 113-123. |
Johnson, et al., “Glucose-Dependent Modulation in Insulin Secretion and Intracellular Calcium Ions by GKA50, a Glucokinase Activator”, Diabetes, vol. 56, Jun. 2007, pp. 1694-1702. |
Kappler-Tanudyaya, et al., “Combination of Biotransformation and Chromatography for the Isolation and Purification of Mannoheptulose”, Biotechnology J. 2007, 2, 692-699. |
Katzmarzyk, “The Metabolic Syndrome: An Introduction”, Appl. Physiol. Nutr. Metab., 32, pp. 1-3 (2007). |
Kibenge, et al., “Identification of Biochemical Defects in Pancreatic Islets of fa/fa Rats”, Obesity Research, 3(2), pp. 171-178, Mar. 1995. |
Klain, et al., “Mannoheptulose and Fatty Acid Synthesis in the Rat”, The Joumal of Nutrition, pp. 473-477, 1974. |
Langhans, et al., “Changes in Food Intake and Meal Patterns Following Injection of D-Mannoheptulose in Rats”, Behavioral and Neural Biology, 38, pp. 269-286 (1983). |
Maklashina, et al., “Is Defective Electron Transport at the Hub of Aging”, Aging Cell, vol. 3, 21-27, 2004. |
Mermelstein, Food Technology, 51(10), p. 96, 1997. |
Pelicano, et al., “Glycolysis Inhibition for Anticancer Treatment”, Oncogene, 2006, 25, pp. 4633-4646. |
Rezek, J. Nutr. 106:143-157, 1972. |
Rezek, et al., “Insulin Dependence of Paradoxical Overeating: Effect of Mannoheptulose, Somatostatin, and cycloheximide”, The American Physiological Society, 1979, E205-E211. |
Robey, et al., “Akt, Hexokinase, mTOR: Targeting Cellular Energy Metabloism for Cancer Therapy”, Drug Discovery Today: Disease Mechanisms, vol. 2, No. 2, 2005, pp. 239-246. |
Roth, Ann. Ny Acad. Aci., 928: 305-315, 2001. |
Scruel, et al., “Interference of D-Mannoheptuloase with D-Glucose phosphorylation, Metabolism, and Functional Effects: Comparison between Liver, Parotid Cells and Pancreatic Islets”, Molecular and Cellular Biochemistry, 187, pp. 113-120, 1998. |
Sener, et al., “Environmental Modulation of D-Fructose Insulinotropic Action”, Acta Diabetol, 1998, 35, pp. 74-76. |
Shimada, “Significance of 1,5-Anhydro-D-Glucitol in Diabetes Mellitus Management”, Sangyo Igaku, 1994, 36(3), pp. 148-449. |
Simon, et al., “Insulin and Proinsulin Secretion and Action”, Israel J. Med. Sci., vol. 8, No. 6, Jun. 1972. |
Walker-Bone, et al., “Natural Remedies in the Treatment of Osteoarthritis”, Drugs and Aging, 2003, 20(7), pp. 517-526. |
Wamelink, et al., “Detection of Transaldolase Deficiency by Quantification of Novel Seven-Carbon Chain carbohydrate Biomarkers in Urine”, J. Inherit Metab Dis, (2007), 30, pp. 735-742. |
Winnock, et al., “Correlation Between Gaba Release from Rat Islet beta-cells and their Metabolic State”, Am. J. Physiol Endocrinol. Metab., 282: E937-E942, 2002. |
Wood, et al., “Evidence for Insulin Involvement in Arginine- and Glucose-Induced Hypercalciuria in Rat”, J. Nutr., 113, pp. 1561-1567, 1983. |
Zhang, et al., “Dissimilar Effects of D-Mannoheptulose on the phosphorylation of alpha vs beta-D-glucose by either Hexokinase or Glucokinase”, International Journal of Molecular Medicine, 14, pp. 107-112, 2004. |
Andus, et al., “Imbalance of the Interleikin 1 System in Colonic Mucosa-Association with Intestinal Inflammation and Interleukin 1 Receptor Agonist Genotype 2”, Gut, vol. 31, 1997, pp. 651-657. |
Anonymous, “The Best Ever Guacamole—Again, Whole Foods Market”, Jan. 18, 2013, Retrieved from the Internet: URL:http://www.wholefoodsmarket.com/blog/best-ever-guacamole-again, p. 3. |
Apgar, et al., “Effect of feeding Various Levels of Bifidobacterium globosum A on the Performance, Gastrointestinal Measurements and Immunity of Weanling Pigs and on the Pelfromance and Carcass Measurements of Gorwing-Finishing Pigs”, J. Animal Science, 1993, vol. 71, pp. 2173-2179. |
Aranda, et al., “Analysis of Intestinal Lymphocytes in Mouse Colitis Medicated by Transfer of CD4+, CD45RB High T Cells in SCID Recipients”, 1997, The American Assoc. of Immunologists. |
Arany, et al., “The Effect of Carcinogens and Non-Carcinogens on Some Biochemical Features of the Mouse Lung Tissue”, Arch. Toxicol., Suppl. 4, 73 (1980). |
Asahara, et al., “Antimicrobial Activity of Intraurethrally Adminstered Probiotic Lactobacillus casei in a Murine Model of Escherichia coliUrinary Tract Infection”, Antimicrobial Agents & Chemotherapy, 2001, 45(6): 1751-1760. |
Barbara, et al., “A Role for Inflammation in Irritable Bowel Syndrome”, Gut, 2002, 51 (Suppl I), pp. i41-i44. |
Begbie, et al., “The Isolation of Some Heptoses, Heptuloses, Octuloses and Nonuloses from Pimula Officinalis JACQ”, Carbohydrate Research, 1966, vol. 2, pp. 272-288. |
Benno, et al., “Individual and Seasonal Variations in the Composition of Fecal Microflora of Beagle Dogs”, Bifidobacteria Microflora, vol. 11, No. 2, pp. 69-76, 1992. |
Biavati, et al., “Electrophoretic Patterns of Proteins in the Genus Bifidobacterium and Proposal of Four New Species”, Journal Int. J. Syst. Bacteriol., vol. 32, pp. 358-373, 1982. |
Bodmeier, “Capsule with Controlled Active Ingredient Release Comprises Active Ingredient Containing Filling, 2, Capsule Shell, Swelling Agent and Water-Insoluble Layer”, BODM, May 18, 1999. |
Botterweck, et al., “Intake of Butylated Hydroxyanisole and Butylated Hydroxytoluene and Stomach Cancer Risk: Results from Analyses in the Netherlands Cohort Study”, Food and Chemical Toxicology, 38 (2000, 599-605. |
Bouhnik, et al., “Effects of Bifidobacterium SP Fermented Milk Ingested with or without Inulin on Colonic Bifidobacteria and Enzymatic Activities in Healthy Humans”, European Journal of Clinical Nutrition, 1996, 50, pp. 269-273. |
Brandtzaeg, et al., “Immunopathology of Human Inflammatory Bowel Disease”, Springer Seminars in Immunopathology, 1997, 18, pp, 555-589. |
Bridigidi, et al., “Specific Detection of Bifidobacterium Strains in a Pharmaceutical Probiotic Product and in Human Feces by Polymerase Chain Reaction”, System Appl. Microbiol., 23, 2000, 391-399. |
Campieri, et al., “Reduction of Oxaluria after an Oral Course of Lactic Acid bacteria at High Concentration”, Kidney International (2001) vol. 60, pp. 1097-1105. |
Chadwick, et al., “Activation of the Mucosal Immune System in Irritable Bowel Syndrome”, Gastroenterology, 2002, 122, pp. 1778-1783. |
Charteris, et al., “Antibiotic Susceptibility of Potentially Probiotic Bifidobacterium Isolates from the Human Gastrointestinal Tract”, Letters in Applied Microbiology, 1998, vol. 26, pp. 333-337. |
Charteris, et al., “Development and Application of an in Vitro Methodology to Determine the Transit Tolerance of Potentially Probiotic Lactobacillus and Bifidobacterium Species in the Upper Human Gastrointestinal Tract”, Journal of Applied Microbiology, 1998, vol. 84, pp. 759-768. |
Charteris, et al., “Effect of Conjugated Bile Salts on Antibiotic Susceptibility of Bile Salt-Tolerant Lactobacillus and Bifidobacterium Isolates”, Journal of Food Protection, vol. 63, No. 10, 2000, pp. 1369-1376. |
Charteris, et al., “Selective Detection, Enumeration and Identification of Potentially Probiotic Lactobacillus and Bifidobacterium Species in Mixed Bacterial Populations”, International Journal of Food Microbiology, 35, 1997, pp. 1-27. |
Chauviere, et al., “Adhesion of Human Lactobacillus Acidophilus Strain LB to Human Enterocyte-like Caco-2 Cells”, Journal of General Microbiology, 1992, vol. 138, pp. 1689-1696. |
Chen, et al., “Action of 5-Thio-D-Glucose and Its 1-Phosphate with Hexokinase and Phosphoglucomutase”, Arch. Biochem. Biophys. 169, pp. 392-396 (1975). |
Chevalier, et al., “Detection of Bifidobacterium Species by Enzymatic Methods”, Journal of Applied Bacteriology, 1990, vol. 68, pp. 619-624. |
Chiricolo, et al., “Cell Adhesion Molecules CD11a and CD18 in Blood Monocytes in Old Age and the consequences for Immunological Dysfunction”, Gerontology, 1995, 41(4), pp. 227-234. |
Cicco, et al., “Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor-Alpha”, The American Society of Hematology, Blood, vol. 75, No. 10, May 15, 1990, pp. 2049-2052. |
Collins, et al., “A Randomised Controlled Trial of a Probiotic Lactobacillus Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity”, Microbial Ecology in Health and Disease, vol. 14, No. 2, Jun. 2002, pp. 81-89. |
Collins, et al., “Selection of Probiotic Strains for Human Applications”, Dairy Journal, 8, 1998, 487-490. |
Cooke, et al., “Role of Estrogens in Adipocyte Development and Function”, Exp. Biol. Med., 229:1127-35, 2004. |
Mane, et al., “The Non-Competitive Inhibition of Brain Hexokinase by Glucose-6-Phosphate and Related compounds”, Biol. Chem., 210, pp. 597-696 (1954). |
Cruzen, et al., “Effects of Caloric Restriction on Cardiovascular Aging in Non-Human Primates and Humans”, Clin. Geriatr. Med., vol. 25(4), pp. 733-743, Nov. 2009. |
De Pergola, “The Adipose Tissue Metabolism: Role of Testosterone and Dehydroepiandrosterone”, Int. J. Obesity, 24: S59-S63, 2000. |
Dent, et al., “Lactobacillus animalis JCM5670”, Database JCM Catalogue, Japan Collection of Microorganisms, 1986, XP002447035. |
Donnelly, et al., “Differential Regulation of II-1 Production in Human Monocytes by IFN-y and IL-4”, The Journal of Immunology, vol. 145, pp. 569-575, No. 2, Jul. 15, 1990. |
Dreau, et al., “Effects of 2-deoxy-D-glucose Adminstration on Immune Parameters in Mice”, Immunopharmacology, vol. 39, Jun. 1, 1998, pp. 201-213. |
Dunne, et al., “Probiotics: From Myth to Reality, Demonstration of Functionality in Animal Models of Disease and in Human Clinical Trials”, Antonie Van Leeuwenhoek. Jul.-Nov. 1999;76(1-4):279-92. |
Eisai, “Sustained-Release Solid Preparation of Zero Order Drug Releasing Profile Comprises Granules Obtainable by Coating Inner Core Containing Xanthine Deriv. Etc, with Film of Hardened Oil”, EISA, Dec. 22, 1989. |
Fajans, et al., “Stimulation of Insulin Release in the Dog by a Nonmetabolizable Amino Acid. Comparison with Leucine and Arginine”, J. of Clinical Endocrinology and Metabolism, 33(1) 35-41, Jul. 1971. |
Fontana, et al., “Long-term Calorie Restriction is Highly Effective in Reducing the Risk for Artherosclerosisin Humans”, PNAS, vol. 101(17), pp. 6659-6663 (2004). |
Freund, “Capsule Containing Useful Enteric Bacteria-includes Hydrophobic Layer Non-fluid at Room Temp Isolating Bacteria from Membrane, to prevent Moisture Penetration”, Derwent Publ. Ltd. FREN, Aug. 5, 1986. |
Gasche, et al., “IL-10 Secretion and Sensitivity in Normal Human Intestine and Infalmmatory Bowel Disease”, Journal of Clinical Immunology, vol. 20, No. 5, 2000. |
Gatrell, et al., “The Effects of Chocolate and Chocolate by-product Consumption on Wild and Domestic Animals”, Chocolate in Health and Nutrition, Humana Press, 2013, pp. 135-141. |
German, et al., “Glucose Sensing in Pancreatic Islet Beta Cells: The Key Role of Glucokinase and the Glycolytic Intermediates”, Proc. Nat. Acad. Sci., 90, 1781-1785 (1993). |
Gibson, et al., “Dietary Modulation of the Human Gut Microflora Using Probiotics”, Journal of Nutrition, 1998, 80, suppl 2, S209-S212. |
Gielkens, et al., “Effects of Hyperglycemia and Hyperinsulinemia on Satiety in Humans”, Metabolism, vol. 47, No. 3, pp. 321-324, 1998. |
Van Damme, et al., “The Proportion of Th 1 Cells, Which Prevail in Gut Mucosa, is Decreased in Inflammatory Bowel Syndrome”, 2001, Blackwell Science Ltd. Clinical and Experimental Immunology, 125, pp. 383-390. |
Vickers, et al., “Comparison of Fermentation of Selected Fructooligosaccharides and Other Fiber Substrates by canine Colonic Microflora”, AJVR, vol. 62, No. 4, Apr. 2001. |
Voet, et al., Biochemistry, John Wiley & Sons, Inc., pp. 1044-1045. |
Wein, et al., “Analyzing a Bioterror Attack on the Food Supply: The Case of Botolinum Toxin in Milk”, 2005, The National Academy of Sciences of the USA. |
Weindruch, “The Retardation of Aging by Caloric Restriction”, Toxicol. Pathol., 1996, 24:742. |
Willott, et al., “Aging and Presbycusis: Effects on 2-Deoxy-D-Glucose Uptake in the Mouse Auditory Brain Stem in Quiet”, Exp. Neurol., vol. 99(3), pp. 615-621. |
Yaeshima, et al., “Bifidobacterium globosum, Subjective Synonym of Bifidobacterium pseudolongum, and Descrption of Bifidobacterium pseudolongum subsp. pseudolongum com nov. and Bifidobacterium psuedolongum subsp. globosum comb. nov.”, Systematic and Applied Microbiology, 1992, vol. 15(3), pp. 380-385. |
Yamamoto, et al., “Changes in Behavior and Gene Expression Induced by Caloric Restriction in C57BL/6 Mice”, Physiological Genomics, vol. 39, No. 3, Sep. 8, 2009, pp. 227-235. |
Yang, et al., “The Role of Voltage-Gated Calcium Channels in Pancreatic [beta]-Cell Physiology and Pathophysiology”, Endocrine Reviews, vol. 27, No. 6, Oct. 1, 2006. |
Yu, “Aging and Oxidative Stress: Modulation by Dietary Restriction”, Free Radical Biology and Medicine, vol. 21, No. 5, pp. 651-668, 1996. |
All Office Actions, U.S. Appl. No. 09/950,052 (now abandoned). |
All Office Actions, U.S. Appl. No. 10/842,300. |
All Office Actions, U.S. Appl. No. 11/313,198 (now abandoned). |
All Office Actions, U.S. Appl. No. 11/313,199 (now abandoned). |
All Office Actions, U.S. Appl. No. 12/012,317. |
All Office Actions, U.S. Appl. No. 12/082,710. |
All Office Actions, U.S. Appl. No. 12/168,400. |
All Office Actions, U.S. Appl. No. 12/371,101. |
All Office Actions, U.S. Appl. No. 12/371,266. |
All Office Actions, U.S. Appl. No. 12/638,128. |
All Office Actions, U.S. Appl. No. 12/716,533. |
All Office Actions, U.S. Appl. No. 12/762,539. |
All Office Actions, U.S. Appl. No. 12/939,594. |
All Office Actions, U.S. Appl. No. 13/098,741. |
All Office Actions, U.S. Appl. No. 13/098,756. |
All Office Actions, U.S. Appl. No. 14/043,142. |
Amendment in response to Nonfinal Office Action mailed Aug. 16, 2011 and issued in connection with U.S. Appl. No. 12/716,540 dated Nov. 15, 2011. |
Amendment in response to Nonfinal Office Action mailed Jun. 10, 2011 and issued in connection with U.S. Appl. No. 12/638,101, Dated Sep. 2, 2011. |
Amendment in response to Nonfinal Office Action mailed Jun. 7, 2011 and issued in connection with U.S. Appl. No. 12/716,518 dated Oct. 7, 2011. |
Amendment in response to Nonfinal office Action mailed Jun. 9, 2011 and issued in connection with U.S. Appl. No. 12/716,562, dated Sep. 2, 2011. |
Dorland's Pocket Medical Dictionary (24th ed.), W.B. Saunders Co. p. 15, 1989. |
European Search Report Received in Connection with EP 04 81 5182, mailed on Jun. 13, 2008. |
European Search Report Received in Connection with EP 04 81 5186, mailed on Jan. 7, 2013. |
Final Office Action issued in connection with U.S. Appl. No. 12/638,101, mailed Dec. 30, 2011. |
Final Office Action issued in connection with U.S. Appl. No. 12/716,518 mailed Jan. 4, 2012. |
Final Office Action issued in connection with U.S. Appl. No. 12/716,540 mailed Jan. 10, 2012. |
Final Office Action issued in connection with U.S. Appl. No. 12/716,562 mailed Dec. 29, 2011. |
International Search Report for PCT/US2011/058861, dated Feb. 10, 2012. |
International Search Report for PCT/US2012/035921, dated Jul. 10, 2012. |
International Search Report for PCT/US2012/036035, dated Jul. 11, 2012. |
International Search Report Received in Connection with PCT/US2004/043068, mailed on Sep. 25, 2007. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/638,101, mailed Jun. 10, 2011. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716,540, mailed Aug. 16, 2011. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716,562, mailed Jun. 9, 2011. |
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716518 mailed Jun. 7, 2011. |
Physician's Desk Reference, 1963 Edition, Medical Economics, Inc. Oradell, N.J., 1962, Product Identification Section, SEction Four, p. VIII and XI. |
Supplemental Amendment in response to Nonfinal Office Action mailed Jun. 10, 201, and issued in connection with U.S. Appl. No. 12/638,101, dated Sep. 29, 2011. |
LabScan XE User's Manual, Manual Version 1.2, A60-1010-862, Jan. 2003, 53 pp. |
“Changing Times”, The Kiplinger Magazine, vol. 31, No. 1, Jan 1977, pp. 39-40. |
“Lactobacillus animalis genes for 16S-23S intergenic spacer region, 23S ribosomal RNA, strain”, Database EMBL: JCM 5670, Jul. 9, 2004, XP002447038. |
“Lactobacillus murinus genes for 16S-23S intergenic spacer regions, 23S ribosomal RNA, strain: JCM 1717”, Database EMBL, Jul. 9, 2004, XP002447039. |
“Nutrient Profiles for Dog Foods”, Association of American Feed Control Officials Incorporated, pp. 110-119, 1994. |
Alves-Filho, Drying Technology, 2002, vol. 20, No. 8, pp. 1541-1557, abstract. |
Anand, et al., “Cytokines and Inflammatory Bowel Disease”, Tropical Gastroenterology, 1999, 20(3), pp. 97-106. |
Anderson, et al., Nutrition Reviews, vol. 61, No. 5, pp. S17-S26, May 2003. |
Naaz, et al., “THe Soy Isoflavone Genistein Decreases Adipose Deposition in Mice”, Endocrinology, 144 (8):3315-3320, 2003. |
Novogrodsky, et al., “Lymphocyte Transformation Induced by Concanavalin A and its Reversion by methyl-alpha-D-mannopyranoside”, Biochim. Biophys. Acta, 1971, 228, 579-583. |
Obaldiston, et al., “Microflora of Alimentary Tract of Cats”, American Journal of Veterinary Research, vol. 32, No. 9, Sep. 1971, pp. 1399-1405. |
O'Callaghan, et al., “Differential Cytokine Response of Cells Derived from Different Lymphoid Compartments to Commensal and Pathogenic Bacteria”, Gastroenterology, Apr. 2003, vol. 124, Issue 4, Supplement 1, p. A339. |
O'Mahony, et al., “Probiotic Human Bacteria: Selection of a New Strain and Evaluation in Vitro and In Vivo”, Gastroenterology, vol. 118, No. 4, Apr. 2000. |
O'Mahony, et al., “Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout mice”, Aliment Pharmacol Ther., 2001, 15, pp. 1219-1225. |
Panwala, et al., “A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdria, Spontaneously Develop Colitis”, The American Association of Immunologists, 1998. The Journal of Immunology, 1998, 161, pp. 5733-5744. |
Park, et al., “Species Specific Oligonucleotide probes for the detection and identification of Lactobacillus isolated from mouse feces”, Journal of Applied Microbiology, 2005, vol. 99, pp. 51-57, XP002447051. |
Pawelec, et al., “T Cell Immunosenescence In Vitro and In Vivo”, Exp. Gerontol, 1999, 34: 419-429. |
Perlmann, et al., “Inhibition of Cytotoxicity of Lymphocytes by Concanavalin A in vitro”, Science, 1970, 168:1112-1115. |
Powrie, et al., “Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in Scid Mice Reconstituted with CD45Rbhi CD4+ T Cells”, Immunity, vol. 1, pp. 553-562, Oct. 1994. |
Purina, “Advancing Life Through Diet Restriction”, The Purina Pet Institute Symposium, 2002. |
Raonimalala, et al., “Action of Soluble Carbohydrates from Avocado Fruit on Utilization of Calcium in the Rat”, Ann. Nutr Aliment, 34(4), 734-744, 1980. |
Rastall, “Baceria in the Gut: Friends and Foes and How to Alter the Balance”, The Journal of Nutrition, Waltham Intl Science Symposium: Nature, Nurture, and the Case for Nutrition (2004), pp. 2022S-2026S. |
Reid, et al., “Prevention of Urinary Tract Infection in Rats with an Indigenous Lactobacillus Casei Strain”, Infection and mmunity, 1985, 49(2), pp. 320-324. |
Riquelme, et al., “Regulation of Carbohydrate Metabolism by 2,5-Anhydro-D-Mannitol”, PNAS, 80, pp. 4301-4305 (1983). |
Rodtong, et al., NCBI Genbank Accession No. AF080100, NCBI Genbank (1998). |
Roe, et al., “Further Studies of the Physiological Availability of Heptoses”, J. Biol. Chem., 121:37-43, 1937. |
Rogler, et al., “Cytokines in Inflammatory Bowel Disease”, World Journal of Surgery, vol. 22, 1998, pp. 382-389 KP002296948. |
Rowland, et al., “Physiological and Behavioral Responses to Glucoprivation in the Golden Hamster”, Physiology and Behavior, vol. 30, No. 5, May 1, 1983, pp. 747-747. |
Ruscetti, et al., “Release of Colony-Stimulating Activity from Thymus-Derived Lymphocytes”, J Clin Invest. 1975;55 (3):520-527. |
Sayegh, et al., “Impact of Hormone Replacement Therapy on the Body Mass and Fat Compositions of Menopausal Women: A Cross-Sectional Study”, Menopause, 6:312-315, 1999. |
Scardovi, et al., “Deoxyribonucleic Acid Homology Relationships Among Species of the Genus Bifidobacterium”, Int. J. Syst. Bacteriol., vol. 21, pp. 276-294, 197. |
Scardovi, “Irregular Nonsporing Gram-Positive Rods”, Genus Bifidobacterium Orla Jensen, 1924, 472. |
Schmitt, et al., “The Immunostimulatory Function of IL-12 in T-Helper Cell Development and its Regulation by TGF-B, IFN-y and IL-4”, Chem. Immunet Basel Karger, 1997, vol. 68, pp. 70-85. |
Scrimshaw, et al., “Interactions of Nutrition and Infection”, Am. J. Med. Sci., 1959, 237: 367-403. |
Shanahan, et al., “Genes, Bacteria and T Cells: Ingredients for Inflammatory Bowel Disease”, Selected Summaries, Gastroenterology, 1998, 115, pp. 1595-1600. |
Shanahan, “The Intestinal Immune System”, Physiology of the Gastrointestinal Tract, 3rd. ed., 1994. |
Silva De Ruiz, et al., “Effect of Lactobacilli and Antibiotics on E. coli Urinary Infections in Mice”, Biol. Pharm. Bull., 1996, 19(1): 88-93. |
Simon, et al., “Metabolism of Mannoheptulose in the Rat. I. Diabetogenic Action”, Arch. Biochem. Biophys., 69, pp. 592-601 (1957). |
Simpson, et al., “Genomic Diversity and Relatedness of Bifidobacteria isolated from a Porcine Cecum”, Journal of Bacteriology, Apr. 2003, vol. 185, pp. 2571-2581. |
Snow Brand Milk Products, “Enteric Capsules—comprising Core Contaiing Drug etc. AndCoating of Hardened Oil of M. Pt. Higher than Body Temp and Disintegrated by Lipase in Intestine”, SNOW, Mar. 31, 1986. |
Sols, et al., “Substrate Specificity of Brain Hexokinase”, Biol. Chem. 210, pp. 581-595 (1954). |
Soudeyns, et al., “The Moving Target: Mechanisms of HIV Persistance During Primary Infection”, Immunology Today, Oct. 1999. |
SS Pharmaceutical KK, “Tablets Containing Double-Coated Granules-Obtained by Coating with Insol. Polymer, Enteric Polymer and/or Waces, Then Further Coating with Water or Acid-Soluble Polymer”, SSSE, Aug. 18, 1988. |
Stallmach, et al., “Induction and Modulation of Gastrointestinal Inflammation”, Trends Immunology Today, Oct. 1998, vol. 19, No. 10, pp. 438-441. |
Strober, et al., “Reciprocal IFN-Gamma and TFG-Beta Responses Regulate the Occurrence of Mucosal Inflammation”, Immunol. Today, Feb. 18, 1997, 2, pp. 61-64. |
Sung, et al., “The Sphincter of Oddi is a Boundary for Bacterial Colonization in the Feline Biliary Tract”, Microbial Ecology in Health and Disease, 1990, vol. 3, pp. 199-207. |
Sunvold, et al., “Dietary Fiber for Dogs: IV. In Vitro Fermentation of Selected Fiber Sources by Dog Fecal Inoculum and In Vivo Digestion and Metabolism of Fiber-Supplemented Diets”, J. Anim. Sci., vol. 73, 1995, 1099-1109. |
Takeda Chemical Ind KK, “Dry Coated Tablet—Comprises Core Tablets Containing Enzyme Prepn in Enteric Films Within Outer Shell”, Take, May 10, 1982. |
Tomomatsu, “Health Effects of Oligosaccharides”, 1994, Food Technology, 48, pp. 61-65. |
Trovatelli, et al., “Presence of Bifidobacteria in the Rumen of Calves Fed Different Rations”, Appl. Environ. Microbiol., 1976, vol. 32(6), pp. 470-473. |
Valente, et al., “Immunologic Function in the Elderly After Injury—The Neutrophil and Innate Immunity”, The Journal of Trauma Injury, Infection and Critical Care, vol. 67, No. 5, pp. 968-974, Nov. 2009. |
Miller, et al., “2-Deoxy-D-Glucose-Induced Metabolic Stress Enhances Resistance to Listeria monocytogenes Infection in Mice”, Physiology & Behavior, vol. 65., No. 3, pp. 535-543, 1998, 1998, 535-543. |
Miller, et al., “The Metabolic Stressor 2-Deoxy-D-Glucose (2-DG) Enhances LPS-Stimulated Cytokine Production in Mice”, Brain, Behavior, and Immunity, 1993, vol. 7, pp. 317-325, 1993, 317-325. |
Ogawa, Journal of Japan Mibyou System Association, 2004, vol. 10, No. 1, p. 140-142 (with machine translation), 2004, 140-142. |
Takayanagi, J. Nippon Med. Sch., 2003, vol. 70, No. 1, p. 71 (with machine translation), 2003, 71. |
Goldrosen, et al., “Impaired Lymphocyte Blastogenic Response in Patients with Colon Adenocarcinoma: Effects of Disease and Age”, Journal of Surgical Oncology, 9:229-234, 1977. |
Golkar, et al., “Apigenin Inhibits Pancreatic Cancel Cell Proliferation via Down-Regulation of the GLUT-1 Glucose Transporter”, Gastroenterology, vol. 130, No. 4, Jul. 22, 2006. |
Grajales-Lagunes, et al., “Stability and Sensory Quality of Spray Dried Avocado Paste”, Drying Technology, Vo. 17, No. 1&2, 1999, pp. 317-326. |
Greetham, et al., “Bacteriology of the labrador dog gut: A cultural and genotype approach”, J. Appl. Microbiol., 93:640-646, 2002. |
Groux, et al., “Regulatory T Cells and Inflammatory Bowel Disease”, Viewpoint Immunology Today, Oct. 1999. |
Hammarstrom, et al., “Mitogenic Leukoagglutinin from Phaseolus vulgaris Binds to a Pentasaccharide Unit in N-acetyllactosamine-type Glycoprotein Glycans”, Proc. Natl. Acad. Sci. USA, 79, 1611-1615 (1982). |
Hemme, et al., “Lactobacillus murinus JCM1717”, Database JCM Catalogue, Japan Collection of Microorganisms, 1982, XP002447036. |
Hershkovitz, et al., “Ethylene regulation of Avocado Ripening Differs Between Seeded and Seedless Fruit”, Postharvest Biology and Technology, vol. 56, No. 2, May 1, 2010, pp. 138-146. |
Hildesheim, et al., “Simultaneous Measurement of Several Cytokines Using Small Volumes of Biospecimens”, Cancer Epidemiology, Biomarkers & Prevention, vol. IK1, pp. 1477-1484, Nov. 2002, abstract. |
Hoffman, et al., “Diabetogenic Action of 5-Thio-D-glucopyranose in Rats”, Biochemistry, vol. 7, pp. 4479-4483 (1968). |
Hommes, et al., “Anti- and Proinflammatory Cytokines in the Pathogenesis of Tissue Damage in Crohn's Disease”, 2000 Lippincott Williams and Wilkins, pp. 1363-1950. |
Isolauri, et al., “Probiotics: A Role in the Treatment of Intestinal Infection and Inflammation?”, Gut, 2002, 50 (Suppl III), pp. iii54-iii59. |
Iwasaki, et al., “Unique Functions of CD11b+, CD8a+ and Double Negative Peyer's Patch Dendritic Cells”, 2001, The American Association of Immunologists. |
Jay, et al., “Metabolic Stability of 3-O-Methyl-D-Glucose in Brain and Other Tissues”, J. Neurochem., 55, pp. 989-1000 (1990). |
Johnston, “Small Intestinal Bacterial Overgrowth”, The Veterinary Clinics of North America, Small Animal Practice, Mar. 1999, vol. 29, No. 2, Mar. 1999, pp. 523-550. |
Kalani, et al., “Effects of Caloric Restriction and Exercise on Age-Related, Chronic Inflammation Assessed by C-Reactive Protein and Interleukin-6”, J. Gerontol. A. Bio. Sci. Med. Sci., vol. 61(3), pp. 211-217 (2006). |
Kaufman, et al., “Identification and Quantification of Bifidobacterium Species Isolated from Food with Genus-Specific 16S rRNA-Targeted Probes by Colony Hybridization and PCR”, Appl. Environ. Microbiol., Apr. 1997, vol. 63, pp. 1268-1273. |
Koizumi, et al., “Influences of Dietary Restriction and Age on Liver Enzyme Activities and Lipid Peroxidation in Mice”, J. Nutr., 117: 361-367, 1987. |
Kok, et al. , “Specific Detection and Analysis of a Probiotic Bifidobacterium Strain in Intact Feces”, Applied and Environmental Microbiology, 1996, vol. 62, pp. 3668-3672. |
Kudo, et al., “An Electron Microscopic Study on Bifidobacterium Pseudolongum SS-24 with Extracellular Material and Naked Bifidobacterium Thermophilum SS-19”, AJAS, vol. 2, No. 3, pp. 444-445, 1989. |
Kyoto, “Sustains-Release Formulation which Floats in Stomach-Comprises Core of Fats and Oils, Coated with Drug Containing Layer of e.g., Agar”, KYOT, Jul. 10, 1987. |
La Forge, “D-Mannoketoheptose, A New Sugar from the Avocado”, J. Biol. Chem. 28:511-22, 1917. |
Lab Prod Ethiques Ethypharm, “Coated Microgranules Containing a Gastric Proton Pump Inhibitor with Two Hydrophobic Materials, Free from Alkali and any Ionic Surfactant”, Derwent Publications Ltd., Ethi., May 21, 1999. |
Lakatos, “Immunology of Inflammatory Bowel Diseases”, Acta Physiological Hungarica, vol. 87 (4), pp. 355-372, 2000. |
Leblond-Bourget, et al., “16S rRNA and 16S to 23S Internal Transcribed Spacer Sequence Analysis Reveal Inter- and Intraspecific Bifidobacterium Phylogeny”, International Journal of Systemic Bacteriology, vol. 6, No. 1, Jan. 1996, pp. 102-111. |
Leclercq-Meyer, et al., “Effects of D-mannoheptulose and Its Hexaacetate Ester on Hormonal Secretion From The Perfused Pancreas”, International Journal of Molecular Medicine, 2000, vol. 6, pp. 143-152. |
Lee, “Medicinal Plant Composition Suitable for Each Blood Type”, WPI/Thomson, vol. 2004, No. 46, Mar. 22, 2004. |
Libby, “Inflammatory mechanisms: the molecular basis of inflammation and disease”, Nutr. Rev., Dec 2007, 65 (12 Pt. 2): S140-6. |
Mamula, et al., Gastrointestinal Tract Infections—Chapter 11. 2004, pp. 79-89. |
Marteau, et al., “Potential of Using Lactic Acid Bacteria for Therapy and Immunomudulation in Man”, FEMS Microbiology Reviews, 12, 1993, pp. 207-220. |
Masoro, “Overview of Caloric Restriction and Aging”, Mech. Aging Dev., vol. 126, pp. 913-922 (2005). |
Massi, et al., NCBI Genbank Accession No. AB102854, NCBI Genbank (1994). |
Mattarelli, et al., “Characterization of the plasmid pVS809 from Bifidobacterium globosum”, Microbiologica, 1994, vol. 17, pp. 327-331. |
Mattson, et al., “Beneficial Effects of Intermittent Fasting and Caloric Restriction on the Cardiovascular and Cerebrovascular Systems”, J. Nutr, Biol. 16, 3:129-137, 2005. |
McCarthy, et al., “Double Blind Placebo Controlled Trial of Two Probiotic Strains in Interleukin”, Gastroenterology, vol. 122, No. 4, suppl., 1, pp. A389-A390, DDW Meeting Abstract, Nr. T962. |
McCracken, et al., “Probiotics and the Immune System”, in G. W. Tannock (ed.), Probiotics, a critical review. Horizon Scientific Press, Norfolk, United Kingdom, 1999, p. 85-112. |
McGee, et al., “A Synergistic Relationship Between TNF-alpha, IL-1B, and TGF-B1 on IL-6 Secretion by the IEC-6 Intertinal Epithelial Cell Line”, Immunology, 1995, 86, pp. 6-11. |
McKay, et al., “Review Article: In Vitro Models in Inflammatory Bowel Disease”, Aliment Pharmacol. Ther., 1997, 11 (suppl. 3), pp. 70-80. |
Mentula, et al., “Comparison Between Cultured Small-Intestinal and Fecal Microbiotas in Beagle Dogs”, Applied and Environmental Microbiology, Aug. 2005, vol. 71, No. 8, p. 4169-4175. |
Meyer, et al., “Long-Term Caloric Restriction Ameliorates the Decline in Diastolic Function in Humans”, J. Am. College of Cardiology, vol. 47(2), pp. 398-402 (2006). |
Mitsuoka, et al., “Ecology of the Bifidobacteria.”, The American Journal of Clinical Nutrition, Nov. 1977, vol. 30, pp. 1799-1810. |
Mohamed, et al., “Effect of Long-Term Ovariectomy and Estrogen Replacement on the Expression of Estrogen Receptor Gene in Female Rats”, Eur. J. Endocrinol., 15, 142:307-14, 2000. |
Molteleone, et al., “Manipulation of Cytokines in the Management of Patients with Inflammatory Bowel Disease”, Ann. Med, Nov. 2000, 32(8), pp. 552-560. |
Morishita Jintan KK, “Capsule Preparation for Enteral Adminstration of Unsaturated Fatty Acids”, Derwent Publications Ltd, MORI, Oct. 30, 1997. |
Moustafa, et al., “Effects of aging and antioxidants on glucose transport in rat adipocytes”, Gerontology, 1995, 41 (6)301-7. |
“A Balanced Diet”, Waltham Book of Dog and Cat Nutrition, Ed. ATB, Edney, Chapter by A. Rainbird, pp. 57-74, Pergamon Press, Oxford, 1988. |
“Kidney Stones in Adults (http://kidney.niddk.nih.gov, pp. 1-14).”, cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005. |
“Mice and Rats”, (www.petswarehouse.com, pp. 1-5), cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005. |
“Probiotic Basics”, (www.usprobiotics.org.basics/, p. 1-12), cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005. |
“Urinary Tract Infections in Adults”, (http://kidney.niddk.nih.gov, pp. 1-11), cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005. |
Arai, et al., “Cytokines: Coordinates of Immune and Inflammatory Responses”, Annu. Rev. Biochem., 1990, 59: 783-836. |
Barrows, et al., “Diet and Nutrition”, Walleye Culture Manual, R. C. Summerfelt, editor, NCRAC Culture Series 101, North Central Regional Aquaculture Center Publications Office, Iowa State University, Ames, First Edition, 1996. |
Collins, “Probiotics and Man—The Host Microbe Interface”, Abstracts, Gastroenterology, vol. 116, No. 4, Apr. 1999. |
Favier, et al., “Fecal B-D-Galactosidase Production and Bifidobacteria are Decreased in Crohn's Disease”, Digestive Diseases and Sciences, vol. 42, No. 4, Apr. 1997, pp. 817-822. |
Fujisawa, “Long-Acting Oral Prepn.—comprises Rapidly Soluble Inner Layer and Sustained Release Outer Layer, Both Layers Containing Principal Agent, which is Coronary or Peripheral Vasodilator”, FUJI, Sep. 20, 1991. |
Hillsvet, “Hill's Presciption Diet, A New Way to Define Pet Obesity”, Internet Article, 2010, http://www.hillsvet.com/conference-documents/Weight—ManagementfTherapeutic?Weight—Reduction—Program/BFI—Backgrounder—pdf. |
McBrearty, et al., “Probiotic Bifidobacteria and Their Identification Using Molecular Genetic Techniques”, Teagasc, Dairy Products Research Centre, Moorepark, Fermoy, Co., Cork, Ireland, Department of Microbiology, University College, Cork Ireland, In, J. Buttriss and M. Saltmarsh (ed), 2000, p. 97-107, Royal Society of Chemistry, Cambridge, United Kingdom. |
Medaglini, et al., “Mucosal and Systemic Immune Responses to Recombinant Protein Expressed on the Surface of the Oral Commensal Bacterim Streptococcus gordonil after Oral Colonization”, Proc. Nat. Acad. Sci. USA, vol. 92, pp. 3868-6872, Jul. 1995, Medical Sciences. |
Morishita Jintan KK, “Yogurt for Supply Physiologically Important Intestinal Bacteria—Contains Bacteria contained in Capsule Havingn Inner Layer Made of Digestible Substance and Outer Layer Dissolving in Intesting”, MORI, Mar. 10, 1995. |
Murphy, et al., “Evaluation and Characterisation of Probiotic Therapy in the CD45RB Transfer Model of Colitis”, AGA Abstracts, Gastroenterology, vol. 116, No. 4, Apr. 1999. |
O'Callaghan, et al., “Human Cytokine Production by Mesenteric Lymph Node Cells in Response to Probiotic and Pathogenic Bacteria”, Gastroenterology, vol. 122, No. 4, Suppl. 1., pp. A -151 DDW Meeting Abstract No. S1043, Apr. 2002, XP09036734. |
O'Halloran, et al., “Adhesion of Potential Probiotic Bacteria to Human Epithelial Cell Lines”, Departments of Microbiology and Medicine, University College, Mercy Hospital, Cork, Ireland, Dept of Surgery, Mercy Hospital Cork, Ireland, 1998. |
O'Mahony, et al., “Probiotic Bacteria and Pathogenic Bacteria Elicit Differential Cytokine Responses from Dendritic ells”, Gastroenterology, 120(5) 1625, Suppl., Apr. 1, 2001, Xp-001097379. |
O'Mahony, et al., “Probiotic Bacteria and the Human Immune System”, Proceedings of the British Nutrition Foundation/Royal Society of Chemistry (Food Chemistry Group) “Functional Foods '99—Claims and Evidence”. BNF (London), 2000, pp. 63-70. |
Schrek, et al., “Characterizatoin of the B Lymphocyte Response to Pokeweed Mitogen”, Annals of Clinical and Laboratory Science, 1982, vol. 12, Issue 6, pp. 455-462. |
Stagg, et al., “The Dendritic Cell: Its Role in Intestinal Inflammation and Relationship with Gut Bacteria”, Gut, 2003: 52: 1522-1529. |
Tesfay, et al., “Anti-Oxidant Levels in Various Tissues During the Maturation of ”Hass“ Avocado”, Journal of Horticultural Science and Biotechnology, (2010) 85(2): 106-112. |
Seikagaku jiten (third edition), Tokyo Kagaku Dojin Publishing Co., Inc., 1998, pp. 657-658. |
Number | Date | Country | |
---|---|---|---|
20080260866 A1 | Oct 2008 | US |
Number | Date | Country | |
---|---|---|---|
60898788 | Feb 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10842301 | May 2004 | US |
Child | 12012317 | US |